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This dissertation elucidates several independent molecular mechanisms that 
function in astrocytes and glial tumor cells, and suggest that developmental and 
inflammatory signals may contribute to the development of brain tumors. First, we 
analyzed the mechanism of TIMP-1 activation in astrocytes and glioblastoma cells. 
TIMP-1 expression is activated by IL-1, which is the major neuroinflammatory cytokine, 
via simultaneous activation of IKK/NF-κB and MEK3/6/p38/ATF-2 pathways in primary 
xx 
human astrocytes. In contrast to astrocytes, TIMP-1 is expressed at lower levels in 
glioblastomas, and is not regulated by IL-1 due to either dysfunctional IKK/NF-κB or 
MEK3/6/p38/ATF-2 activation. Thus, we propose a novel mechanism of TIMP-1 
regulation, which ensures an increased supply of the inhibitor after tissue injury to limit 
the ECM degradation. This mechanism does not operate in gliomas, and may in part 
explain the increased invasiveness of glioma cells. 
Inflammation has been associated with the development of several cancers, 
including glioblastoma multiforme. However, it has not been linked to other brain 
tumors. Here we show for the first time that inflammation is associated with 
oligodendroglioma tumors as pro-inflammatory cytokines, such as OSM, IL-6, MCP1, 
MIP1α, and MIP1β and inflammatory markers, such as ACT and COX-2, were expressed 
at higher levels in oligodendroglioma samples. In addition, cytokine-induced STAT3 
signaling, but not NF-κB, is highly activated in the oligodendroglioma patients. 
Moreover, OSM promotes oligodendroglioma cell proliferation in vitro, and this effect is 
mediated through STAT3. In summary, oligodendroglioma tumors secrete and respond to 
inflammatory mediators, with OSM being the major cytokine that activates STAT3 to 
promote the growth of tumor cells, and express ACT and COX-2 as a hallmark of 
ongoing inflammation.  
Since STAT3 promotes the growth of oligodendroglioma, as well as glioblastoma 
cells, and also regulates gliogenesis, we studied molecular mechanisms of this process in 
xxi 
an in vitro differentiation model. We turn our attention to the NFI family of transcription 
factors since they have recently emerged as novel regulators of the development of 
vertebral neocortex. We developed a stem cell-neural progenitor-astrocyte differentiation 
model, in which the generated astrocytes were characterized by proper morphology, 
increased glutamate uptake, and expression of early and late astrocyte markers. 
Moreover, we found that NFI-X and NFI-C but not NFI-A or NFI-B, control the 
expression of GFAP and SPARCL1, the markers of terminal differentiation of astrocytes. 
In summary, the three mechanisms of gene regulation we studied, provided new 
insights into astrocyte biology, with the important implications for understanding the 
basis leading to the development and progression of brain tumors. 
 




1.1. Inflammation in the brain. 
Inflammation involves recruitment and activation of circulating leukocytes, 
including macrophages, neutrophils, dendritic cells (DC), natural killer cells (NK) and T 
lymphocytes from the blood vessels to the sites of injury. This process is accompanied by 
expression of integrins, adhesion molecules, extracellular proteinases, and secretion of 
chemokines and cytokines. In normal, physiological conditions, inflammation is self-
limiting, as it is followed by an anti-inflammatory response leading to its resolution and 
restoration of the homeostasis. However, sustained inflammation is the major contributor 
to numerous diseases, including rheumatoid arthritis, psoriasis, inflammatory bowel 
disease, autoimmune and cardiovascular diseases, diabetes, and cancer (44). 
In the past, the brain was considered an immune-privileged site due to the 
presence of the blood/brain barrier, which effectively controls the passage of selected 
cells and molecules from the blood into the brain. More recently this dogma has been 
reevaluated, as critical data emerged indicating that inflammation is the primary response 
of the central nervous system (CNS) to injury, infection, and disease (134, 207). 
Alzheimer’s and Parkinson’s diseases, stroke, depression, schizophrenia, epilepsy, 
multiple sclerosis, and traumatic brain injury are all associated with inflammation in the 
brain (134). They share a common histopathological response, termed as the reactive 
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astrogliosis, which is characterized by a presence of reactive astrocytes and activated 
microglia (19, 147). These cells are capable of secreting and responding to pro-
inflammatory cytokines and growth factors, which results in their proliferation and 
migration to the site of inflammation and subsequent repopulation of affected tissue. 
Interleukin-1 (IL-1), Interleukin-6 (IL-6), and Tumor Necrosis Factor α (TNFα) are the 
major inflammatory cytokines involved in the inflammatory process in the brain. They 
induce the expression of inflammation-associated enzymes, including inducible nitric 
oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), which produce additional 
inflammatory mediators such as nitric oxide (NO), and prostaglandins (PGE2), 
respectively. Pro-inflammatory cytokines further exert their effects by controlling the 
expression of genes encoding integrins, adhesion molecules, proteinases and their 
corresponding inhibitors to enable cell migration and extracellular matrix (ECM) 
remodeling. 
1.2. Metalloproteinases and their inhibitors (MMPs/TIMPs). 
Turnover of extracellular matrix (ECM) occurs in normal development, 
morphogenesis, reproduction processes, tissue remodeling, wound healing, and 
angiogenesis (26, 211). There are many types of proteinases that participate in ECM 
remodeling, including serine, cysteine, aspartic, and metallo-proteinases. The metallo-
proteinases (MMP) (33) not only degrade the matrix but modulate the activity and release 
of biologically active molecules, as well. They constitute a big family of 24 members 
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divided into four major groups: collagenases, gelatinases, stromelysins, and membrane 
type MMPs (MT-MMPs). They are either extracellular or membrane-bound enzymes, 
which require both a zinc atom and zymogen activation for their enzymatic activity. 
MMP concentrations are regulated at the transcriptional level by cytokines, growth 
factors and hormones, while their enzymatic activity is strictly controlled by α2-
macroglobulin and specific tissue inhibitors of metalloproteinases (TIMPs) (67). In fact, a 
balance must be maintained between MMP activity and inhibition in a healthy tissue, 
while any deviation from it leads to arthritis, tumor cell invasion and metastasis, 
periodontal disease, neurodegenerative disorders, atherosclerosis, and fibrosis. In the 
brain, MMPs and TIMPs are linked to synaptic plasticity, neuronal activity, and spatial 
learning. Indeed, expression of MMPs and TIMPs has been described in the cerebellum 
and the hippocampus and specific MMP substrates such as dystroglycan, integrins and 
neurotrophins have been identified in the brain (105). Moreover, MMPs and TIMPs are 
involved in brain tumor invasion and spreading, and are up-regulated during 
inflammation (95, 102).  
TIMP-1, -2, -3, -4 (tissue inhibitors of metalloproteinases) are four relatively 
small proteins of 20-30 kDa, sharing approximately ~40% sequence similarity and 
containing 12 conserved cysteine residues (26). Their N-terminal domain binds non-
covalently to the active zinc-binding site of the MMPs and is necessary, and sufficient, 
for the inhibition (73). In most cases different TIMPs are capable of inhibiting most of 
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the MMPs, but each TIMP is also capable of specific binding to a specific MMP at a site 
distinct from the active site. In fact, TIMPs inhibit the catalytic enzyme site through the 
N-terminal domain alone (100), but they specifically interact with the target by their C-
terminal domains. Therefore, there are certain differences in specificity, for example 
TIMP-2, -3, but not TIMP-1 are effective inhibitors of MT-MMPs while TIMP-3 is the 
only one to inhibit tumor necrosis factor α converting enzyme (TACE).  
1.3. TIMP-1. 
Human TIMP-1 is an inducible glycoprotein, composed of 184 amino acids with 
an apparent molecular mass ranging from 28.4 to 34 kDa. In contrast, TIMP-2 is a non-
glycosylated protein expressed constitutively in most of the tissues whereas TIMP-3 is a 
non-glycosylated protein bound tightly to ECM components that promotes the 
detachment of transformed cells. TIMP-4 is expressed at high levels in the human heart 
and has been shown to cause apoptosis (26). Human TIMP-1 gene is located on the X 
chromosome at Xp11.3-11.23 and encodes a 0.9 kb mRNA (9). The TIMP-1 promoter is 
conserved between rodents and humans and it lacks a classical TATA box. It contains 
functional binding sites for activator protein 1 (AP-1), polyoma enhancer A binding 
protein-3 (Pea3), and signal transducers and activators of transcription (STATs) located 
within a 22 bp serum response element (SRE), as well as binding site for specificity 
protein 1 (SP-1) and leader-binding protein-1 (LBP-1) (9, 122). In addition, there is an 
upstream TIMP-1 element (UTE-1) in the vicinity of the SRE, which binds runt-related 
5 
transcription factors RUNX (15, 197). All these regulatory elements contribute to TIMP-
1 up-regulation by multiple stimuli such as phorbol esters, TGFβ, EGF, retinoids, IL-6, 
OSM and LIF (22, 84, 196).  
Interestingly, TIMPs have multiple functions independent of their MMP 
inhibiting activity. In fact, TIMP-1 was discovered as an erythroid-potentiating factor 
(57) and was shown to have growth and survival-promoting activity for normal and 
transformed cells (73, 86, 124). TIMP-1 was later isolated from cartilage as an 
antiangiogenic factor (144) and, therefore, it is believed that TIMPs inhibit cellular 
invasion, tumorigenesis, metastasis, and angiogenesis. In addition, TIMP-1 and TIMP-2 
suppress the apoptosis of mouse B cells and melanoma cells (81, 199). These effects of 
TIMP-1 are exerted through its binding to an unidentified receptor and a number of 
signalling cascades. For example, Ras and Raf-1, which regulate cell proliferation and 
apoptosis, are activated upon TIMP-1 stimulation in osteosarcoma cells (205). Moreover, 
TIMP-1 displays its anti-apoptotic and pro-survival activity by the activation of PI3K, 
Bad phosphorylation, and Bcl-XL release in erythroid, myeloid, human breast epithelial, 
and Burkitt’s lymphoma cells (124). TIMP-1 was also reported to activate MAPKs, 
including p38 and ERK1/2 in various cell types (130, 162). More recent studies revealed 
that TIMP-1 induced hematopoietic cell differentiation through activation of the 
MEKK1/MEK6/P38a signalling pathway as a downstream target of caspase-3 (48). More 
importantly, TIMP- 1 can be found in the nucleus of gingival and human fetal lung 
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fibroblasts (216), and it also binds to the cell surface and translocates to the nucleus of 
MCF-7 breast carcinoma cells (172). As suggested, TIMP-1 could inhibit nuclear MMPs, 
such as MMP-11, to prevent cleavage of nuclear membrane proteins, and thus exert an 
anti-apoptotic effect. In addition, TIMP-1 was demonstrated to interact with the 
transcriptional repressor promyelocytic leukemia zinc finger protein (PLZF), an 
interaction that blocks PLZF-mediated apoptosis (170).   
It has been shown that TIMPs are expressed in a cell-, time- and site-specific 
manner. TIMP-1, for example is regulated developmentally in rats, as its expression is 
low during embryogenesis, increases just before birth and later decreases during the 
postnatal period (67). TIMP-1 has also been shown to possess divergent functions 
different from MMP inhibition and tissue remodeling as it is involved in stimulation of 
gonadal steroidogenesis, apoptosis, neuroprotection, angiogenesis, changes in cell 
morphology and glioma malignancy. It plays crucial neuroprotective role in the CNS 
through the maintenance of the blood-brain barrier (BBB). TIMP-1 not only inhibits 
MMPs to prevent BBB and tissue damage, but protects neurons against cytotoxic effects 
of glutamate-induced calcium influx, as well. In addition, TIMP-1 is involved in synaptic 
mechanisms underlying learning and memory, particularly those related to the 
hippocampus (32).  Knock-out studies revealed that TIMP-1 KO mice have impaired 
learning and memory but paradoxically are resistant to excitoxicity and do not undergo 
the typical mossy fiber sprouting observed in wild type mice (104).   
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It has been also shown that TIMP-1 increases during the acute inflammation in 
the brain, which is associated with the reactive astrogliosis (102). Therefore, elevated 
TIMP-1 levels are observed in experimental autoimmune encephalitis (EAE), Parkinson’s 
Disease (PD), Multiple Sclerosis (MS), viral infection, and brain tumors. However, in 
chronic inflammation conditions such as HIV-1-associated dementia (HAD), TIMP-1 
levels are significantly reduced in the cerebro-spinal fluid (CSF) and the brain tissue of 
patients (192). These findings suggest that TIMP-1 is secreted as part of an attempted 
tissue repair mechanism and may be protective during acute inflammation. On the 
contrary, a prolonged exposure to pro-inflammatory stimuli leads to the failure of TIMP-
1 production followed by extensive tissue damage, which causes neuronal malfunction 
and disease.  
It was observed that TIMP-1 levels are also elevated in neurinomas and 
meningiomas suggesting that TIMP’s trophic activity may enhance the malignancy of 
certain types of tumors (67). In fact, high TIMP-1 levels are also correlated with glioma 
malignancy. In contrast, the more aggressive CNS tumors express lower levels of TIMPs 
than either benign tumors or normal brain. In addition, overexpression of TIMP-1, -2, -3 
reduced tumor cell growth while recombinant TIMP-1 decreased glioma cell invasion. 
Given the versatility of functions of TIMP-1, it is unclear whether this protein is 
beneficial or detrimental to the growth and progression of brain tumors. Our data suggest 
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that TIMP-1 may not be beneficial for glioblastoma progression and likely plays a 
neuroprotective role during astrogliosis-associated conditions in the brain (Chapter 2).  
IL-1 is the major neuro-inflammatory cytokine linked to at least eight major 
diseases in the brain involving inflammatory responses in which astrocytes are the key 
players (204). Therefore, we investigated whether IL-1 is directly responsible for the 
TIMP-1 gene up-regulation in human primary astrocytes. As a result, we identified a 
novel mechanism of TIMP-1 gene up-regulation by IL-1 in these cells. Interestingly, this 
mechanism is not functional in glioblastoma cells (Chapter 2).  
1.4. Alpha-1-antichymotrypsin 
Alpha-1-antichymotrypin (ACT) is a glycoprotein with a molecular weight of 55-
66 kDa, which belongs to the serpin family (serine proteinase inhibitors). Serpins are 
present in the plasma at physiological conditions and are drastically elevated in response 
to acute inflammation. They are synthesized in the liver upon cytokine stimulation, and 
they protect against extensive tissue damage by inhibiting leukocyte-derived proteases 
(191). ACT inhibits the activity of cathepsin G and chymases released from neutrophils 
and mast cells, respectively (88). In addition, ACT inhibits cell-bound chymotrypsin-like 
enzymes and thus reduces the cytotoxic activity of natural killer cells (97). It is expressed 
in multiple tissues, including liver, heart, lungs, kidney, brain, breast and prostate. The 
ACT gene has been classified as a type II positive acute phase gene according to its 
regulatory pattern in the liver (114).   
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In the brain, it is part of a ‘cerebral’ acute phase response as its levels are elevated 
in response to pro-inflammatory stimuli during inflammation-associated diseases such as 
Alzheimer’s disease (AD) (135). ACT expression is induced by the pro-inflammatory 
cytokines belonging to the IL-6 family that activate the signal transducers and activators 
of transcription proteins (STATs) (117). Precisely, STAT3 homodimers bind the two cis-
elements in the promoter of the act gene, located at –125 to –117 and –95 to – 87 
upstream of the ACT transcription start site. Moreover, ACT expression is also triggered 
by cytokines from the IL-1 family, namely IL-1 and TNFα in primary human astrocytes 
and U373 glioblastoma cells (116). These cytokines exert their stimulatory effect through 
activation of nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) transcription 
factors, which subsequently bind to the astrocyte-specific enhancer located –13 kbp 
upstream of the ACT transcription start site.  
In the CNS, the ACT gene expression was demonstrated in astrocytes and brain 
endothelial cells in addition to glioblastoma cells (116, 117). Since ACT is such an 
excellent marker of local inflammation in the brain, we used it to assess whether 
inflammation is associated with oligodendroglioma tumors (Chapter 3).  
 1.5. Interleukin-1 (IL-1). 
Interleukin-1 (IL-1) is a pleiotropic cytokine, activating variable signalling 
pathways in different cell types. It is implicated in inflammation, stress responses, 
tumorigenesis, invasiveness and metastasis of cancer cells, and angiogenesis. In a healthy 
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brain, IL-1 is expressed at low levels by resident brain cells. It is implicated in a slow-
wave sleep, and modulation of synaptic plasticity. In addition, it is involved in 
neuroendocrine responses and appetite suppression by mediating leptin actions in the 
brain. More importantly, IL-1 is associated with responses to local and systemic insults as 
its expression dramatically increases in response to injury or infection. Thus IL-1 is 
believed to be the major mediator of neuroimmune responses and is mainly produced by 
microglia, the brain resident macrophages. However, astrocytes, neurons, 
oligodendrocytes, cerebrovascular cells and circulating immune cells that invade the 
brain during inflammatory conditions also produce IL-1 (76, 103, 174, 204).  
IL-1 is a family of three closely related proteins: agonists IL-1α and IL-1β, and an 
antagonist IL-1ra (3, 23, 138, 190). They all bind to two IL-1 receptors: type I receptor 
(IL-1RI) that signals through NF-κB and MAPK pathways, and type II receptor (IL-1RII) 
that lacks the intracellular domain and does not initiate any signal transduction (21, 56, 
70). Binding of IL-1α or IL-1β to IL-1RI initiates the formation of a complex with IL-1 
receptor accessory protein (IL-1RAcP). This causes recruitment of a cytosolic adaptor, 
myeloid differentiation primary response protein-88 (Myd88), which attracts IL-1 
receptor associated kinase (IRAK). Hyperphosphorylated IRAK subsequently interacts 
with an E3 ubiquitin ligase TNF receptor associated factor-6 (TRAF6), transforming 
growth factor β- activating kinase-1 (TAK1), and a regulatory TAK1-binding subunit 
(TAB1, 2, 3). Subsequently, a complex consisting of TRAF6-TAK1-TAB1-TAB2-TAB3 
11 
dissociates into the cytoplasm, where TAK1 is activated through auto-polyubiquitination 
of TRAF6 and auto-phosphorylation. In fact, the TAB proteins are required for ubiquitin-
dependent activation of TAK1 by TRAF6. TAK1, as a member of the mitogen-activated 
protein kinase kinase kinase (MAPKKK) family, subsequently phosphorylates mitogen-
activated protein kinase kinases MKK3/6, MKK4/7, which leads to the activation of p38 
and JNK, respectively. On the other hand, TAK1 also phosphorylates the IκB kinase 
(IKK). The IKK complex consists of two catalytic subunits IKKα and IKKβ and an 
essential regulatory subunit NEMO/IKKγ. Activated IKKβ phosphorylates a cytoplasmic 
inhibitor of NF-κB α (IκBα), which results in its ubiquitination and subsequent 
degradation by the proteasome. This releases the bound NF-κB transcription factor 
(p50/p65) and results in its nuclear localization and DNA binding. The p65 subunit also 
undergoes several post-translational modifications such as phosphorylation, acetylation, 
and prolyl isomerization that affect transcriptional activity of target genes. The rapid 
activation and nuclear translocation of cytoplasmic NF-κB (p50/p65) is often referred to 
as the ‘classical’ or ‘canonical’ pathway. It occurs in response to inflammatory cytokines 
such as tumor necrosis factor (TNF)-α and IL-1, or activation of a T-cell receptor by 
lipopolysaccharide (LPS). IKKα can also be phosphorylated by NF-κB inducing kinase 
(NIK), another target of TAK1, which leads to the activation of the alternative (non-
canonical) NF-κB pathway. IKKα dimer phosphorylates the p100 NF-κB subunit, 
induces its proteolysis, leading to the formation of a p52/RelB complex that binds to κB 
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sites of target genes. Thus, stimuli that activate both the canonical and non-canonical 
pathways lead to the activation of different sets of subunits of the NF-κB complex, which 
results in the activation of various target genes. 
1.6. MAPK pathway. 
 Mitogen-activated protein kinases (MAPK) are a family of serine/threonine 
protein kinases widely conserved among eukaryotes that are involved in the regulation of 
multiple cellular processes including proliferation, differentiation, mobility and death 
(106, 140). MAPK signaling cascades are organized hierarchically into three-tiered 
modules, activated by subsequent phosphorylation. Mitogens and cytokines act on a 
receptor and trigger a cascade by recruiting the MAPK kinase kinase (MAPKKK), which 
is the first, membrane, proximal component of the cascade. Subsequently, MAPKKKs 
phosphorylate MAPK kinases (MAPKK), which in turn phosphorylate MAPKs that 
eventually target transcription factors. There are several standard MAPK cascades, 
namely the Raf-MEK1/2-ERK1/2 pathway, the TAK-MKK3/6-p38 pathway, the 
MEKK1,4-MKK4/7-JNK pathway, and the MEKK2,3-MEK5-ERK5 pathway. They are 
generally activated by various stimuli in response to stress, cytokines, growth factors, and 
mitogens. 
13 
1.7. Oncostatin M (OSM). 
Oncostatin M (OSM) belongs to the IL-6 family of cytokines, which also include 
interleukin-6 (IL-6), interleukin-11 (IL-11), cilliary neurotrophic factor (CNTF), 
leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), and cardiotrophin-like cytokine 
(CLC).  
OSM is a secreted glycoprotein, expressed mainly by cells of monocytic origin 
such as monocytes, macrophages and microglia, but also in neutrophils, T cells, 
osteoblasts, Kaposi’s sarcoma cells, dendritic cells, and normal testis (37). Its expression 
is induced by granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-
3 (IL-3), human chorionic gonadotropin (hCG), HIV-1 infection, LPS, PMA, as well as 
prostaglandin E2 (PGE2). OSM signals through the type I (gp130/LIFR), and type II 
(gp130/OSMRβ)  receptor complexes. OSΜ  activates STAT1, 3, 5, ERK1/2 and p38, 
but not JNK. In addition, OSM-activated signaling can be negatively regulated by SOCS3 
and PIAS3. 
OSM is a cytokine with both pro- and anti-inflammatory actions (37). It is 
associated with the initiation of host defense, as it is expressed by activated T cells, 
macrophages and microglia. In the CNS, OSM is not detected in the normal brain; 
however, its immunoreactivity is positive in MS and HAD patients, where it is localized 
to activated microglia, hypertrophic astrocytes and infiltrating leukocytes. OSM 
stimulates the expression of IL-6, MCP-1 and TIMP-1 in astrocytes and brain endothelial 
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cells, and elevates the expression of MMP-1, -3 in astrocytes. Moreover, OSM regulates 
the expression of the urokinase plasminogen activator (uPA) and the plasminogen 
activator inhibitor-1 (PAI-1), which contribute to cell invasion and tissue remodeling. 
Anti-inflammatory actions of OSM have been demonstrated in the mouse EAE model, 
where OSM proved to have protective effects. 
Increased levels of OSM have also been detected in some brain tumors, including 
astroglioma, glioblastoma multiforme and pituitary adenoma, when compared to the non- 
neoplastic brain biopsy samples (118). The role of OSM in these tumors is ambiguous, 
since it exerts both, growth promoting and inhibitory effects (38). For example, OSM 
inhibits the growth of human glioma cells in vitro and tumor formation in vivo. On the 
other hand, it stimulates the expression of VEGF, and hence it is pro-angiogenic, which 
correlates with glioma progression.  
The roles of OSM in the development and progression of other brain tumors have 
not been described. Therefore, we investigated the effects of OSM and OSM-activated 
JAK/STAT pathway in the growth of oligodendroglioma tumors (Chapter 3). 
1.8. JAK/STAT pathway. 
IL-6 family of cytokines is a group of neuropoietic factors with pluripotent and 
redundant biological functions in cell proliferation, apoptosis, migration, and cellular 
differentiation. This is mainly due to the fact that they all share a signal transducer 
receptor subunit, the gp130 protein, which heterodimerizes with specific receptor 
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subunits upon ligand binding (128, 159). This leads to the activation of the Janus kinases 
(Jak1, Jak2, Jak3, Tyk2), which phosphorylate tyrosine residues of the gp130 protein and 
attract Src-homology-2 (SH-2) domain containing signaling molecules, including STATs. 
Having bound to the receptor complex, STATs are phosphorylated, dimerize and 
translocate to the nucleus to bind to the specific IFN-γ activation sequence (GAS) 
elements and activate gene transcription. There are seven STAT proteins identified in 
mammals: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6. All except 
for STAT2 form homodimers. In addition, STAT1 with STAT2, and STAT1 with STAT3 
heterodimerize, and several STATs can form tetramers. Not only does the tyrosine 
phosphorylation of STATs enable DNA binding but allows them to remain in the 
nucleus, as well. In fact, STATs require facilitated transport into the nucleus through 
binding to importin-α5, and they remain there until the phosphorylation mark is removed 
by nuclear phosphatases, such as TC45.  
Moreover, there are a few negative regulators of JAK/STAT signaling (128). 
These include cytoplasmic tyrosine phosphatases, such as SH2-containing phosphatase 
(SHP1, SHP2), and protein-tyrosine-phosphatase 1B (PTP1B), which target both the 
receptor and kinase phosphorylation sites. Another group of cytoplasmic inhibitors are 
suppressors of cytokine signaling (SOCS), which bind to the receptors and Jaks to block 
further STAT activation. These cytokine-induced proteins can also cause ubiquitin-
proteasome mediated degradation of the receptor protein and associated signaling 
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molecules. Protein inhibitors of activated STATs (PIAS) constitute another level of 
negative STAT regulation in the nucleus. PIAS proteins interact with tyrosine-
phosphorylated STATs and block their DNA-binding, thus inhibiting gene activation. 
Taking all these positive and negative regulators into consideration, activation versus 
inhibition of the JAK/STAT signaling is crucial to their variable biological functions. 
IL-6 family of cytokines can also activate MAPK pathways through the gp130 
protein (89). In this case, activated Jak1 and Jak2 phosphorylate SHP2, which acts as a 
docking target for the adaptor protein Grb2. Grb2 is complexed with GTP-exchange 
factor SOS that interacts with Ras, which in turn, recruits Raf and activates a MAPK 
pathway.  
A typical inflammatory response involves the activation of NF-kB, Jak/Stat and 
MAPK signalling pathways due to the presence of the proinflammatory cytokines of the 
IL-1 and IL-6 families, growth factors, and other mitogens. 
1.9. Inflammation in cancer. 
Normal inflammation is self-limiting, as it is followed by an anti-inflammatory 
response. However, persistent and excessive presence of pro-inflammatory stimuli and/or 
failure of systems to resolve the inflammatory response result in chronic inflammation. 
Indeed, chronic inflammation contributes to tumor development and progression by 
creating tumor-supporting microenvironment rich in inflammatory cells, cytokines, 
growth and survival factors, facilitating genomic instability, and promoting angiogenesis 
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(44, 129, 193). The mediators produced by inflammatory cells regulate the growth of 
fibroblasts, neoplastic and endothelial cells. Later during tumor progression, neoplastic 
cells divert inflammatory mechanism to favor their growth and development and subvert 
anti-tumor immune cell functions. Therefore, chronic inflammation caused by a parasite, 
bacterial or viral infection is the main driving force of anaplastic progression. There are 
many examples of chronic inflammatory diseases that lead to cancer. The strongest 
evidence is found for colon cancer that is associated with inflammatory bowel diseases. 
In addition, infection with the hepatits C virus predisposes to liver carcinoma, 
schistosomiasis increases the risk of bladder and colon cancers and Helicobacter Pylori is 
a well-established carcinogen in the gastric cancer (44). Chronic inflammation is also 
associated with necrotic centers of glioblastoma tumors in the brain (166, 200). Since 
nothing is known about the role of inflammation in the biology of oligodendroglioma 
tumors, we investigated whether inflammatory mediators are produced in these tumors 
and whether they affect the oligodendroglioma growth (Chapter 3).  
1.10. Classification of neurological tumors. 
 Neuroectodermal (neurological) tumors include all tumors that originate from the 
cells of the central or peripheral nervous system (PNS). Based on the histology, 
cytogenetic, and molecular genetic profiling, the World Health Organization (WHO) 
classifies tumors into four grades: I, II, III and IV, which reflect their degree of 
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malignancy (112). Histological features of malignancy include high cellularity, cellular 
pleomorphism, mitotic activity, microvascular proliferation, and necrosis. 
Brain tumors constitute less than 2% of all malignant neoplasms (112). However, 
many of them affect children and are a second cause of death after leukemias. Since they 
affect the brain, they are devastating for patients and highly expensive to treat (127). 
Tumors of neuroepithelial tissue are responsible for nearly half of all brain tumor 
incidences, and they include astrocytic, oligodendroglial, ependymal, neuronal, pineal, 
embryonal, choroid plexus tumors and mixed gliomas. Glial tumors are the most common 
in adults, as glial cells retain the ability to proliferate throughout life, while neurons 
become post-mitotic past the development stages. Glial tumors are classified in 
subgroups according to whether they display differentiated features of astrocytes, 
oligodendrocytes or ependymal cells (218). In fact, glioblastomas and astrocytomas 
constitute ~30%, and oligodendrogliomas ~4% of all reported brain tumors, which ranks 
them second and third, respectively in terms of incidence after meningioma. 
Schwannoma and neurofibroma are the two most common glial tumors in the 
PNS (218). They are considered benign and classified as grade I according to WHO 
guidelines. Schwannoma is a neural crest derived tumor that is clonal in origin and 
possesses morphological and molecular features of Schwann cells. In contrast, 
neurofibroma is a heterogenous tumor composed of cells of different origin, including 
schwann cells, fibroblasts, neurons and others.  
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1.11. Glioblastoma. 
 There is a great variety of astrocytic tumors, which are widely represented by 
glioblastomas, the most aggressive and fatal type of brain tumor (127). Pilocytic 
astrocytoma, grade I is benign and can be surgically removed, whereas grade II diffuse 
astrocytoma, is of low malignancy and requires long-term clinical treatments. Anaplastic 
astrocytoma, grade III, is malignant and leads to the patient’s death within a few years, 
while glioblastoma multiforme (GBM), grade IV is highly malignant and causes death 
within months. In fact, GBM is the most malignant form of a glial neoplasm, and it 
carries the worst clinical prognosis among primary brain tumors in adults. Neither of the 
approaches, including diagnostic imaging, neurosurgery, radiation therapy, and 
chemotherapy manages to significantly improve the accurate prognosis or patient’s 
survival. However, there are several molecular markers that help to characterize these 
tumors (136). These include mutations in the p53 tumor suppressor and retinoblastoma 
(RB) (25%), EGF receptor (EGFR) amplification or overexpression (~40-60% of cases), 
mutations of the phosphatase and tensin homology gene (PTEN) (30%), deletion or 
inactivation of cyclin-dependent kinase inhibitors p16INK4a/p19ARF (30-40%), 
amplification or overexpression of transformed 3T3 cell double minute 2 (MDM2) gene 
(10-50%), and loss of heterozygosity (LOH) on the chromosome 10 in 50-80% of cases. 
As a result of these genetic alterations, activation of signalling pathways such as PI3K-
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Akt, Ras-MAPK and JAK/STAT leads to uncontrolled cellular proliferation and escape 
from apoptosis, which promotes tumor growth and progression.  
1.12. STAT3 in GBMs. 
The STAT3 transcription factor is the most commonly observed member of the 
STAT family to be present in a constitutively activated state in many tumors (93, 212). 
The role of STAT3 in development, proliferation, angiogenesis, and survival of tumor 
cells is well documented. In fact, it is constitutively activated in both the tumor cells and 
immune cells within the tumor microenvironment. Its role is to facilitate communication 
between tumor cells and diverse immune-cell subsets, leading to the suppression of the 
innate and adaptive anti-tumor responses.  
STAT3 is constitutively activated in 90% of glioblastomas, including both the 
primary tumor samples from patients and GBM cell lines. Its persistent activation is due 
to either an autocrine IL-6 signaling (166) or increased expression of the EGF receptor 
(69), and it can be further stimulated by other cytokines, including IL-4 (167). The 
overall anti-apoptotic effects of STAT3 are exerted through activation of anti-apoptotic 
genes such as Bcl-2, Bcl-XL, and Mcl-1 (166). In fact, it was shown that inhibition of 
constitutively active STAT3 with a general Jak inhibitor AG490 or a dominant negative 
of STAT3, suppresses proliferation and induces apoptosis of glioblastoma cells through 
reducing the steady state levels of these pro-survival proteins. Moreover, a novel, specific 
inhibitor of STAT3, WP1066, induces the apoptosis of several glioblastoma cell lines by 
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activation of Bax and suppression of c-myc, Bcl-XL, and Mcl-1, and inhibits the growth 
of subcutaneous tumors (99). Therefore, STAT3 is a candidate therapeutic target in 
malignant gliomas.  
1.13. Oligodendroglioma. 
Oligodendroglioma is the second most common neuroepithelial neoplasm, 
accounting for ~4% of primary brain tumors (113). It can be classified as grade II 
(oligodendroglioma), which is defined as “a well-differentiated, diffusely infiltrating 
tumor of adults that is typically located in the cerebral hemispheres and composed 
predominantly of cells morphologically resembling oligodendroglia”. It can also be 
characterized as anaplastic oligodendroglioma, grade III, which is defined as “an 
oligodendroglioma with focal or diffuse histological features of malignancy and a less 
favorable prognosis”. Most oligodendrogliomas manifest in the adult age groups with a 
peak incidence between the 4th and 5th decades. The most common symptoms include 
seizures, headaches, paralysis, visual loss, papilledema, ataxia, abnormal reflexes and 
meningismus. The vast majority of these tumors occur in the supratentorial brain, 
including the frontal, temporal, parietal and occipital lobes. Surgical resection is the 
mainstay of initial treatment, which is followed by radio- and/or chemotherapy (201). 
The median postoperative survival period for patients with grade II oligodendroglioma 
ranges from 3-17 years. However, for patients with anaplastic oligodendroglioma who 
received surgical and radiotherapy treatments, a median survival time varies only from 10 
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months to 3.9 years. More importantly, 70% of patients with oligodendroglioma have a 
loss of 1p and 19q regions of chromosomes and respond favorably to chemotherapy 
treatment with procarbazine, lomustine and vincristine by increasing the survival rates 
(101). Interestingly, these losses of heterozygosity are speculated to result in the loss of 
DNA repair mechanisms, which together with the p53-mediated apoptosis lead to tumor 
cell death upon administration of the alkylating agents. Therefore, the genetic profile of 
oligodendroglioma can be useful for guiding the treatment and predicting the outcome. In 
contrast to glioblastoma and astrocytoma, oligodendroglioma specific molecular markers 
have not been identified thus far. 
1.14. Gliomagenesis. 
 So far, the research on glial tumorigenesis has raised more questions than answers 
(218). The most current view focuses on cancer stem cells that are found in brain tumors 
and are believed to be responsible for gliomagenesis. However, the dedifferentiation 
theory cannot be ignored, as gliomas do show morphological and molecular 
characteristics of differentiated cells. Astrocytoma and glioblastoma, for example, are 
believed to derive from the astrocytic cell lineage because of glial fibrillary acidic protein 
(GFAP) expression (202), which is expressed in differentiated astrocytes. In addition, 
there is an inverse relationship between the number of GFAP-positive cells and the 
aggressive behavior of gliomas. The high grade GBMs often express low levels of GFAP, 
and are characterized by an increased proliferation rate and invasiveness, whereas the low 
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grade astrocytomas have high levels of GFAP and decreased cell growth rates and 
invasion. 
On the other hand, some astrocytomas also express brain fatty acid-binding 
protein (B-FABP), a marker of radial glial cells that are precursors of astrocytes (71). 
Moreover, GBM has been reported to express neuronal markers suggesting that it may 
develop from neural stem cells. To further support this notion, a subtype of tumor cells 
with characteristics of stem cells such as self-renewal and multipotency, have recently 
been identified in GBMs (213). These cells, named brain tumor stem cells (BTSC) (185), 
express neural progenitor cell markers: nestin and CD133 (14). In addition, when 
compared to their CD133-negative equivalents, they are radio- and chemo- resistant, and 
they have higher expression levels of ABC transporters (11).  
During normal brain development, terminally differentiated astrocytes undergo an 
anti-proliferative and senescent/apoptotic phase (195). However, it is possible that due to 
genetic and signalling alterations, progenitor cells escape from the astrocyte 
differentiation pathway, evade the apoptosis thus proliferating uncontrollably and 
generate glial tumors. Therefore, it is of high importance to understand the mechanisms 
regulating astrocyte differentiation. 
1.15. Differentiation of astrocytes. 
 Astrocytes are critical for many pathological states of the brain (19, 147), such as 
neuroinflammation associated with neurodegenerative diseases and the development and 
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progression of glial tumors. However, the mechanisms controlling astrocyte 
differentiation and gene expression are poorly understood.  The data accumulated over 
the years suggest that several signaling pathways are critical for astrocyte differentiation 
(and expression of astrocyte-specific markers), involving the activation of Smads, JAK-
STAT pathway, the Notch signaling, and the Nuclear Factor-1 (NFI) family of 
transcription factors (143). 
 During the vertebrate embryonic development, neurons are generated first, which 
is followed by glia. This neurogenic-to-gliogenic transition phase occurs on day E18 in 
mice, with neurons generated during days E12-E18, astrocytes appearing on day E18 and 
peaking in the neonatal period, whereas oligodendrocytes develop postnatally (179).  
During the process of astrogliogenesis, several marker genes have emerged as 
characteristic for differentiating astrocytes. These include: glial fibrillary acidic protein 
(GFAP) (62), glutamate transporter (GLAST) (182), glutamine synthase (GS), 
inflammatory secreted protein S100B (219), osteonectin (SPARCL) (141), antigen CD44 
(131), brain lipid binding protein (BLBP), and brain fatty acid binding protein (B-FABP) 
(121). These markers provide useful tools to study gliogenesis.  
The gliogenesis is likely induced by the activation of the JAK-STAT signaling 
pathway in neural precursors in response to neuron-derived cardiotrophin-1 (CT-1) (12).  
In fact, mice lacking subunits of the CT-1 receptor, LIFR or gp130, show substantial 
deficits in astrocyte generation. Moreover, ectopic expression of CNTF, which signals via 
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LIFR and gp130, induces premature astrocyte formation. CT-1, CNTF and LIF mediate 
their effects through STAT3, which is believed to be critical in this process (158) (87). 
Cytokines of the IL-6 family cooperate with bone morphogenic protein-2 (BMP-2) (152, 
210), which in turn signals through Smad1. Subsequently, Smad1 can form a complex 
with STAT3, bridged by the coactivator p300, which is followed by synergistic induction 
of astrogliogenesis (152).  Although STAT3 is strongly suggested to play an instructive 
role in astrogliogenesis, neural-specific conditional knockout of STAT3 does not affect 
astrocyte generation, suggesting that other STATs may functionally substitute for 
STAT3.   
Notch signaling has also been involved in gliogenesis as it leads to activation of 
the transcription factor RBP-Jκ . RBP-Jκ promotes gliogenesis, only when the JAK-STAT 
pathway is turned on (77) (82). RBP-Jκ up-regulates the expression of primary target 
genes of Notch signaling, such as hairy and enhancer of split (HES) transcriptional 
repressor, which inhibits neurogenesis.  
 Recently, it became apparent that the NFI family of transcription factors can also 
play a role in brain development and specifically in gliogenesis (143). However, 
mechanisms linking NFI to previously characterized pathways and expression of 
astrocyte-specific genes are not known. Therefore, we tested a hypothesis that NFI is 
critical for expression of astrocyte marker genes and is thus required for astrogliogenesis 
(Chapter 4). 
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1.16. Nuclear Factor I. 
 The phylogenetically conserved nuclear factor-1 (NFI) regulates the transcription 
of various cellular and viral proteins, in addition to adenoviral DNA replication (79). It 
comprises a family of DNA-binding proteins encoded by four genes in vertebrates: Nfia, 
Nfib, Nfic, Nfix (80, 165). In mammals, the products of the four genes: NFI-A, NFI-B, 
NFI-C and NFI-X are expressed in complex, overlapping patterns during embryogenesis, 
and their expression is developmentally regulated (34). This suggests that they may play 
an important role in regulating the tissue-specific gene expression during mammalian 
embryogenesis (163).  
 NFI factors share a highly homologous, conserved 220-aa N-terminal domain that 
is sufficient for dimerization, DNA-binding, and stimulation of adenovirus DNA 
replication in vitro (79). NFI proteins form homo- and hetero- dimers that bind to the 
dyad symmetric consensus sequence TTGGC(N)5GCCAA with apparently identical 
affinities. However, significant variation occurs within the C-terminal end of the NFI 
proteins, which encodes transcription regulation domains. In addition, transcripts of all 
four genes can be alternatively spliced, yielding as many as nine different proteins from 
each gene (5). Moreover, NFI can be differentially phosphorylated in various cell types 
and this modification affects its transcriptional activity (18). 
 NFI proteins have been implicated in both activation and repression of 
transcription in a gene-, promoter- and cell-type specific manner (35). Several 
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mechanisms of this regulation have been proposed (79). NFI-C was reported to activate 
transcription by a direct interaction with basal transcriptional machinery through a 
proline-rich transactivation domain that is homologous to the CTD repeat of the RNA 
polymerase II. On the other hand, the C-terminal proline-rich domain of NFI-C can also 
interact directly with histone H3. Another activation mechanism involves the repressive 
histone H1, which binds weakly to NFI-binding sites and competes for DNA binding. 
Therefore binding of NFI removes the repressive histone and makes the chromatin 
accessible to other transcriptional regulators. Finally, NFI proteins were shown to recruit 
various co-activators, including p300/CBP and Ski (206). These data suggest that NFI-C 
can activate gene transcription by simultaneous removal of repressive histone H1 and 
recruitment of a co-activator associated with histone H3. Besides transcriptional 
activation by NFI, mechanisms of repression include direct competition with more potent 
transactivators for binding at adjacent or overlapping sites. Moreover, the C-terminal 
transcriptional regulation domains can function as repressors and recruit other co-
repressor proteins, or interact directly with the basal transcriptional apparatus (36, 43). 
All four NFI isoforms are expressed in many tissues, with particularly high levels 
of expression of NFI-A, NFI-B, and NFI-X in the developing neocortex (35). Binding 
sites for NFI factors are present in cellular genes expressed in multiple tissues, but also in 
genes expressed solely in brain, muscle, liver and other differentiated cell types (79). 
There are several NFI-responsive genes in the brain, including GFAP (16), S100B (4), 
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and ACT in astrocytes (75), B-FABP in radial glial cells (18), MBP (myelin basic 
protein) in oligodendrocytes (98), and several neuronal genes (13, 151, 206). Moreover, 
we have recently found that NFI-X controls the expression of both, the ACT and GFAP 
genes in U373 glioma cells (75). Therefore, NFI proteins seem to be involved not only in 
development, but cellular differentiation as well. 
Knock-out studies in mice have strengthened the role of NFI in the brain 
development. Disruption of either Nfia or Nfib gene causes late gestation 
neuroanatomical defects, including agenesis of the corpus callosum, size reduction in 
other forebrain commissures, and loss of specific midline glial populations (47, 184, 
189). In addition, Nfib-deficient mice show aberrant hippocampus and pons formation, 
and defects in lung development. In contrast, disruption of Nfic results in early postnatal 
defects in tooth formation, including the loss of molar roots and aberrant incisor 
development (188). Loss of the Nfix gene is postnatally lethal, and leads to 
hydrocephalus, ventricle enlargement and agenesis of the corpus callosum (58). 
Furthermore, NFI-X-deficient mice develop a deformation of the spine with kyphosis, 
due to a delay in ossification of vertebral bodies and a progressive degeneration of 
intervertebral disks. Moreover, NFI-X was shown to be critical for the replication of the 
JC virus, which selectively infects glial cells (119). These data strongly indicate that NFI-
A, NFI-B and NFI-X proteins are involved in the function and development of the brain.  
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 Recently, it has been elegantly demonstrated that the expression of both NFI-A 
and NFI-B is induced during the neurogenic-to-gliogenic transition (12). The knock-
down of NFI-A prevented the expression of astroglial precursor markers, while the 
misexpression of NFI-A and NFI-B accelerated gliogenesis and migration of astroglial 
precursors into the grey matter. Surprisingly, NFI-A and NFI-B are also needed for the 
initial specification of oligodendroglial precursors, but NFI-A function is later 
compromised in differentiating oligodendrocytes by its direct interaction with Olig2. 
Interestingly, NFI-A expression precedes that of NFI-B in a developing chick embryo, 
suggesting that a cascade of expression of NFI isoforms may exist with NFI-A expressed 
in early stages, followed by NFI-B, and ended with NFI-C and NFI-X.  In fact, human 
multipotent neural progenitors express high levels of NFI-A and NFI-B, but not NFI-X, 
while progenitor-derived astrocytes express all three of these NFI isoforms. All of these 
data indicate that NFI-A and NFI-B are critical in the initial stages of gliogenesis; 
however, the functions of NFI-C and NFI-X are unclear. 
 Based on the facts that NFI-X is involved in the brain development, and is widely 
expressed in the developing neocortex, in addition to regulating the expression of ACT 
and GFAP genes in U373 glioma cells, we investigated whether it is required for terminal 
astrocyte differentiation (Chapter 4). 
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A NOVEL MECHANISM OF TISSUE INHIBITOR OF 




Reactive astrogliosis is the gliotic response to brain injury with activated astrocytes 
and microglia being the major effector cells. These cells secrete inflammatory cytokines, 
proteinases, and proteinase inhibitors that influence extracellular matrix (ECM) 
remodeling. In astrocytes, the expression of tissue inhibitor of metalloproteinases-1 
(TIMP-1)1 is upregulated by interleukin-1 (IL-1), which is a major neuroinflammatory 
cytokine. We report that IL-1 activates TIMP-1 expression via both the IKK/NF-κB and 
MEK3/6/p38/ATF-2 pathways in astrocytes.  The activation of the TIMP-1 gene can be 
blocked by using pharmacological inhibitors, including BAY11-7082 and SB202190, 
overexpression of the dominant-negative inhibitor of NF-κB (IκBαSR), or by the knock-
down of p65 subunit of NF-κB.  Binding of activated NF-κB (p50/p65 heterodimer) and 
ATF-2 (homodimer) to two novel regulatory elements located -2.7 and -2.2 kb upstream of 
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the TIMP-1 transcription start site respectively is required for full IL-1-responsiveness.  
Mutational analysis of these regulatory elements and their weak activity when linked to the 
minimal tk promoter suggest that cooperative binding is required to activate transcription.  
In contrast to astrocytes, we observed that TIMP-1 is expressed at lower levels in gliomas 
and is not regulated by IL-1.  We provide evidence that the lack of TIMP-1 activation in 
gliomas results from either dysfunctional IKK/NF-κB or MEK3/6/p38/ATF-2 activation 
by IL-1.  In summary, we propose a novel mechanism of TIMP-1 regulation, which 
ensures an increased supply of the inhibitor after brain injury, and limits ECM degradation.  
This mechanism does not function in gliomas, and may in part explain the increased 
invasiveness of glioma cells.  
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2.2. INTRODUCTION 
 The remodeling of the extracellular matrix (ECM), including the degradation of the 
ECM by matrix metalloproteinases (MMPs) and its subsequent resynthesis, is critical 
during normal physiological processes, such as angiogenesis, embryonic development, 
organ morphogenesis, bone remodeling, and ovulation (26, 211).  During these processes 
the proteolytic activity of MMPs is tightly controlled at the transcriptional level by growth 
factors, hormones, and cytokines, and at the protein level by proteolytic cleavage of 
inactive zymogens, and the inhibition by specific inhibitors, including tissue inhibitors of 
metalloproteinases (TIMPs) (26).  The delicate balance between the activities of MMPs 
and TIMPs is critical to limit deleterious outcomes of uncontrolled degradation, which is 
manifested in pathological conditions such as periodontal disease, arthritis, tumor cell 
invasion, fibrosis, and neurodegenerative disorders (26, 149, 150).  These pathological 
conditions often represent chronic inflammatory diseases suggesting that inflammatory 
mediators, including inflammatory cytokines, may disrupt the intricate balance between 
MMPs and TIMPs.   
In the central nervous system (CNS), infection and injury induce a 
histopathological response known as reactive astrogliosis, which is the primary cause of 
regenerative failure in the mature CNS (54, 156, 177).  During this response, activated 
astrocytes and microglia secrete MMPs, TIMPs, and a plethora of cytokines and growth 
factors that drastically change the proteolytic balance and affect ECM remodeling (67, 102, 
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192).  IL-1 is one of the major neuroinflammatory cytokines that is detected in the CNS 
after brain injury, and affects the expression of several MMPs and TIMPs in astrocytes, 
microglia, and brain endothelial cells (30, 145, 192).  Thus far, four members of the TIMP 
family (TIMP-1 through TIMP-4) have been identified in mammals (26).  Among TIMPs, 
TIMP-1 is encoded by a highly inducible gene, and is upregulated in several cell types by 
IL-1, IL-6, tumor necrosis factor, epidermal growth factor, transforming growth factor, and 
oncostatin M (OSM).  In the CNS, TIMP-1 expression is upregulated in astrocytes 
following intracranial injury, with TIMP-2 expression upregulated in microglia and 
neurons (102).  Astrocytic TIMP-1 expression is also upregulated in experimental 
autoimmune encephalitis, and in transgenic animals expressing cytokines in the brain 
(160).  However, chronic inflammation associated with HIV-1-associated dementia is 
actually characterized by the decreased levels of TIMP-1 in both cerebrospinal fluid and 
brain tissue, suggesting that prolonged activation of astrocytes leads to TIMP-1 
downregulation and, in turn, ECM degradation (192).  In vitro, IL-1 significantly increases 
TIMP-1 expression in astrocytes, which recapitulates the in vivo findings from acute injury 
models (109, 192).   
Since TIMP-1 upregulation in astrocytes prevents excessive ECM degradation, the 
mechanisms of TIMP-1 regulation may lead to the identification of new therapeutic 
targets.  We initiated this study with the aim of identifying the molecular mechanism that 
regulates TIMP-1 expression in astrocytes exposed to IL-1.   
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2.3. MATERIALS AND METHODS 
2.3.1. Cell culture. Human cortical astrocyte cultures were established using dissociated 
human cerebral tissue established exactly as previously described (117).  Cortical tissue 
was provided by Advanced Bioscience Resources (Alameda, CA), and the protocol for 
obtaining postmortem fetal neural tissue complied with the federal guidelines for fetal 
research and with the Uniformed Anatomical Gift Act.  Human glioblastoma U373-MG 
cells were obtained from American Type Culture Collection (Rockville, MD), whereas 
human glioma A172, U251, and T98G cells were obtained from Dr. Jaharul Haque 
(Cleveland Clinic Foundation, Cleveland, OH).  Cells were cultured in Dulbecco's 
modified Eagle's medium supplemented with 10% fetal calf serum, antibiotics, sodium 
pyruvate, and non-essential amino acids. 
 
2.3.2. Cytokines and cell stimulation. Cells were stimulated with 25 ng/ml OSM (R&D, 
Systems, Inc., Minneapolis, MN), or 10 ng/ml IL-1 (a gift from Immunex Corp., Seattle, 
WA). For inhibitor studies, cells were pretreated with 1 µM SP600125, 10 µM BAY-
117082, 10 µM SB202190, 5 µM parthenolide, 5 µg/ml Actinomycin D (all from Sigma, 
St. Louis, MO), 10 µM GF109203X, or 1 µM CAY10470 (EMD Biosciences, Inc. San 
Diego, CA), and then treated with IL-1.  
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2.3.3. RNA preparation and Northern blot analysis. Total RNA was prepared by phenol 
extraction exactly as described previously (74).  The filters were prehybridized at 65°C for 
3 h in 0.5 M sodium phosphate buffer pH 7.2, 7% SDS, and 1 mM EDTA, and hybridized 
in the same solution with cDNA fragments of TIMP-1 labeled by random priming (64).  
After the hybridization, nonspecifically bound radioactivity was removed by four washes 
in 40 mM phosphate buffer, 1% SDS, and 1 mM EDTA at 65°C for 20 min each. 
 
2.3.4. Quantitative PCR. TIMP-1 mRNA levels were measured using TaqMan 
technology (Applied Biosystems, Foster City, CA) according to the supplier’s instructions.  
Briefly, one µg of total RNA was reverse-transcribed using the High capacity cDNA 
archive kit (Applied Biosystems, Foster City, CA).  Subsequently, the cDNAs were diluted 
100-fold (TIMP-1) or 10,000-fold (18S rRNA).  For real-time PCR, pre-mixed primer-
probe sets and TaqMan Universal PCR Master Mix were purchased from Applied 
Biosystems (Foster City, CA), and cDNAs were amplified using ABI 7900HT cycler.  
 
2.3.5. Synthetic oligonucleotides. The following oligonucleotides were synthesized to 
amplify the DNA fragments from the 5’ flanking region of the TIMP-1 gene: (-1.0+1.0); 
5’-AGGTCCATGGGGAGGGGGCAGGG-3’ and 5’GGGGCCATGGTGGGTTCTGTGG 
GG-3’, (-4.2-0.8); 5’-ACCTGGTACCAGGGTTGTAACTCAGG-3’ and 5’-AAAGGGTA 
CCCGTCCAATCAAGAGAC-3’, (-5.3-4.1); 5’-CCAAGGTACCTTACAGCTTAGAAG-
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3’ and 5’-AGTAGGTACCCGGTTCTGTGGAGTG-3’, (-7.7-7.0); 5’CGGAGCATGCG 
GCAGAGGAATGGAG-3’ and 5’-TCTGGGTCATACAGAACCAG-3’, (-9.4-8.9); 5’ AC 
CTCGGTACCCCCAGCTCAAGTAAG-3’ and 5’-TGGGGCATGCTAGAGAGAGACA 
AGG-3’, (-2.9-2.1); 5’-TGGCTGGTACCTGTAATCCCAGCACTTTGG-3’ and 5’-AGCT 
CTCGAGATGGTCACACACCCC-3’, (-2.9-2.7); 5’-ACCTGGTACCTCCGAGGGAGA 
AGTGAGG-3’ and 5’-GCATCTCGAGGCAGCGGGCCAGGGAAAC-3’, (-3.5-2.7) 5’-
ACCTGGTACCTCCGAGGGAGAAGTGAGG-3’ and 5’-GCATCTCGAGGCAG CGGG 
CCAGGGAAAC-3’, (-3.9-2.7); 5’-ACCTGGTACCTCCGAGGGAGAAGTGAGG-3’ and 
5’-ACAACTCGAGACACCCACAACTCAGTTTG-3’. The following oligonucleotides 
were synthesized to generate the plasmid phT(-0.7m)CAT: 5’-CAGATCTCT CGAGGCA 
TGCGTA-3’ and 5’-TACGCATGCCTCGAGAGATCTGGTAC-3’. The activating 
transcription factor-2 (ATF), activating protein-1 (AP-1), and nuclear factor κB (NF-κB) 
double stranded oligonucleotides used to generate ATF, AP-1, and NF-κB reporter 
constructs, and also in EMSA, had the following sequence: AP-1; 5’-GATCTGTGCTGAC 
TCAGGTTA-3’ and 5’-GATCTAACCTGAGTCAGCACA-3’, NF-κB; 5’-GATCTGGCA 
GGACTTCCCCTGCCA-3’ and 5’-GATCTGGCAGGGGAAGTCCTGCCA-3’, ATF; 5’-
GATCTCGCTTGAGCTCAGGAGA-3’ and 5’-GATCTCTCCTGAGCTCAAGCGA-3’, 
upperNF-κB; 5’-GATCTCCTGGGCACTCCCACCCA-3’ and 5’-GATCTGGGTGGGA 
GTGCCCAGGA-3’, upperATF; 5’-GATCTTGACTGGCGTCATTATA-3’ and 5’-GA TC 
TATAATGACGCCAGTCAA-3’. The mutations within the ATF, AP-1 and NF-κB 
37 
elements were generated using the following primers: AP-1 mutant; 5’-TGAAATCCGGA 
CACAGAGTGTTGCCGAC-3’ and 5’-TGCTGTCCGGAGTTTCAAAGAGTTGGCG 
TCAG-3’, NF-κB mutant; 5’-GGCAGCTCGAGTCCTGCCTTGGCCCCTC-3’ and 5’-CA 
GGACTCGAGCTGCCCTCACTTCTCCCTC-3’, ATF mutant; 5’-CTTGCATATGGGA 
GTTCAAGACCAGTCTGG-3’ and 5’-TCCCATATGCAAGCGATCTGCCTGCCTCA 
GC-3’, upperNF-κB mutant; 5’-CCTGGGCCTGCAGACCCCAACACACATACAGTC-
3’ and 5’-GGGTCTGCAGGCCCAGGAATGTTTTCTGCAAAC-3’, UpperATF mutant; 
5’-TGACTGGTCGACTTATGAGGTGGGCTGAGAGG-3’ and 5’-ATAAGTCGACCA 
GTCATTTGGGAAATGAGG-3’. 
 
2.3.6. Plasmid construction.  Plasmid phT(-1.0)inCAT (containing promoter, first exon, 
first intron, and part of the second exon of the TIMP-1 gene) was generated by inserting 
the 2 kb NcoI-digested PCR product (-1.0+1.0) into the NcoI-digested pCAT3promoter 
vector (Promega, Madison, WI).  Plasmid phT(-0.7)inCAT derives from the plasmid phT(-
1.0)inCAT from which 300 bp KpnI fragment was deleted.  Subsequently, this plasmid 
was digested with NcoI and PstI, ends were blunted, and religated to yield plasmid phT(-
0.7)CAT.  The plasmid phT(-4.2-0.8) was generated by cloning a KpnI-digested PCR 
product into the KpnI sites of phT(-0.7)CAT.  In order to generate all the other reporter 
plasmids containing different fragments of the 5’ flanking region of the TIMP-1 gene, we 
first constructed a plasmid phT(-0.7m)CAT by inserting a double-stranded oligonucleotide 
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into the KpnI/BstZ17I sites of phT(-0.7)CAT (this introduced BglII, SphI, and XhoI sites).  
This plasmid was digested with KpnI, SphI, or StuI to accommodate KpnI-, SphI-, or StuI-
digested PCR products, and yielded the plasmids shown in Fig. 3. Plasmid phT(∆Sac)CAT 
was generated by a deletion of SacI-SacI fragment from the plasmid phT(-4.2-0.8)CAT.  
Plasmid phT(-4.2-0.8) served as the template to construct plasmids with mutated AP-1, 
NF-κB, and ATF sites using the QuikChange XL Site-directed Mutagenesis kit 
(Strategene, La Jolla, CA) according to the manufacturer’s instructions.  Plasmids 
p5xATFCAT, p7xAP-1CAT, and p3xNFκBCAT were generated by cloning corresponding 
double stranded oligonucleotides into the BamHI site of ptkCAT∆EH (117).  The 
expression plasmid pRSVIκB was a gift from Dr. K. Brand (Munich, Germany). 
 
2.3.7. Transient transfections.  Cells were transfected in 12 well clusters using FuGENE6 
transfection reagent (Roche, Indianapolis, IN), according to the supplier’s instructions.  
Plasmids (400 ng of the reporter CAT plasmid and 100 ng of expression plasmid encoding 
β-galactosidase) and 0.6 µl of FuGENE6 diluted into 50 µl of serum free medium were 
used for each well containing cells growing in 500 µl of culture medium.  One day after 
transfection, the cells were stimulated with cytokines, cultured another 24 h, and harvested.  
Protein extracts were prepared by freeze thawing, and the protein concentration was 
determined by the BCA method (Sigma Chemical Co., St. Louis, MO).  Chloramphenicol 
acetyltransferase (CAT) and β-galactosidase assays were performed as described (51).  
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CAT activities were normalized to β-galactosidase activity and are means + S.E.M. (3-7 
determinations). 
 
2.3.8. Downregulation with siRNA. The expression of p65 and ATF-2 was 
downregulated using SMARTpool siRNA purchased from (Dharmacon, Inc. Lafayette, 
CO).  SiRNAs were transfected into cells using Dharmafect 1 (Dharmacon, Inc. Lafayette, 
CO) according to the manufacturer’s instructions. 
 
2.3.9. Nuclear extract preparation and electromobility shift assays (EMSA). Nuclear 
extracts were prepared as described (7).  All oligonucleotides used for EMSA were 
designed to contain four bases single-stranded 5’ overhangs at each end after annealing.  
Double stranded DNA fragments were labeled by filling in 5’ protruding ends with 
Klenow enzyme using [α32P]dCTP (3000 Ci/mmol). EMSA was carried out according to 
the published procedures (65, 180). Briefly, five µg of nuclear extracts and approx. 10 
fmol (10,000 cpm) of probe were used.  Polyclonal anti-ATF-1, anti-ATF-2, anti-CREB, 
anti-c-fos, anti-c-jun, anti-p65, and anti-p50 antisera were purchased from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA).   
 
2.3.10. Western blotting. Cells were lysed in 10 mM Tris pH 7.4, 150 mM sodium 
chloride, 1 mM EDTA, 0.5% NP-40, 1% Triton X-100, 1 mM sodium orthovanadate, 0.2 
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mM PMSF and protease inhibitor cocktail (Roche, Mannheim, Germany).  Samples were 
resolved using SDS-PAGE and electroblotted onto nitrocellulose membranes (Schleicher 
& Schuell, Keene, NH).  Polyclonal anti-ATF-2, anti-p65, and anti-phospho-c-jun antisera 
were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) while anti-
phospho-p38, anti-phospho-p65(Ser536), anti-phospho-ATF-2, and anti-phospho-MEK3/6 
were purchased from Cell Signaling Technology, Inc. (Beverly, MA).  Antigen-antibody 
complexes were visualized by enhanced chemiluminescence according to manufacturer’s 
instructions (Pierce, Rockford, IL). 
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2.4. RESULTS 
2.4.1. Activation of TIMP-1 expression by IL-1 requires ongoing transcription and is 
mediated by multiple signaling cascades. 
IL-1 has previously been shown to upregulate the expression of TIMP-1 in primary 
human astrocytes, (109, 192).  In order to verify these findings, we analyzed TIMP-1 
mRNA expression in response to IL-1 using three independent preparations of primary 
human astrocytes.  For comparison, we also treated these cells with OSM, which has 
previously been shown to upregulate TIMP-1 expression in a number of cell types (22, 
196).  In agreement with previous observations, we found that IL-1 upregulates expression 
of TIMP-1 mRNA (2.5-5 fold depending on the batch of astrocytes), whereas OSM was 
less effective (Fig. 2.1).  Activation of TIMP-1 expression by IL-1 was blocked by 
actinomycin D (Fig. 2.2A), which indicates that ongoing transcription is needed to increase 
TIMP-1 mRNA levels.  Interestingly, the half life of TIMP-1 mRNA was greater than 18h 
in both the control and IL-1-treated cells (Fig. 2.1B), indicating that mRNA stability was 
not enhanced by IL-1. Therefore, the mechanism regulating enhanced transcription of 
TIMP-1 in astrocytes could potentially be targeted using pharmacological approaches to 
ensure sustained upregulation of the inhibitor, which is critical to restrain activity of 
MMPs.  We examined this mechanism using pharmacological inhibitors that specifically 






Fig. 2.1. IL-1 upregulates the expression of TIMP-1 mRNA in human astrocytes.  
Human astrocytes were treated with IL-1 or OSM for 18 hours.  Subsequently, RNA was 
isolated and subjected to Northern blot analysis using TIMP-1 cDNA as a probe.  The 
lower panels show 28S RNA stained with ethidium bromide on the membrane.  Results of 
three independent experiments are shown using three different batches of primary human 







Fig. 2.2. Effect of inhibitors on IL-1-activated expression of TIMP-1 mRNA.  
 Human astrocytes were pretreated with 5 µg/ml Actinomycin D (A) or 1 µM SP600125, 5 
µM BAY11-7082, 10 µM SB202190, 10 µM GF109203X (C) for 1 hour, and subsequently 
stimulated with IL-1 for 18 hours.  (B)  Astrocytes were treated with IL-1 for 18 h, and 
then 5 µg/ml Actinomycin D was added for the indicated time periods.  RNA was isolated, 
and TIMP-1 expression was quantified by real time PCR (using TaqMan technology), 
normalized to 18S rRNA, and expressed as a ratio to untreated cells.  Duplicate 
experiments were repeated three times. 
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inhibitors blocked the IL-1-mediated activation of the TIMP-1 gene, suggesting that 
multiple pathways are involved in its regulation (Fig. 2.2C).  The effective inhibitors 
included BAY11-7082 (an inhibitor of IκB kinase (IKK)), GF109203X (an inhibitor of 
protein kinase C (PKC)), and SB202190 (an inhibitor of p38 kinase), whereas SP600125 
(an inhibitor of c-jun N-terminal kinase) was ineffective.   
 
2.4.2. Identification of the IL-1 regulatory elements of the TIMP-1 gene.   
Multiple regulatory elements have been described within both the 5’ flanking region and 
the first intron of the TIMP-1 gene (15, 22, 29, 40, 49, 84).  In order to examine if IL-1 
responsiveness is mediated by these elements, we generated reporter constructs containing 
either the 1 kb or 0.7 kb long 5’ flanking region of the TIMP-1 gene fused to a CAT 
reporter gene.  In addition, we also generated a construct containing a 0.7 kb long 5’ 
flanking region, the first exon (containing the 5’ untranslated region UTR), the entire first 
intron, and part of the second exon that contains the sequence coding for the first codon of 
the TIMP-1 protein followed by a CAT reporter gene.  Transcription from this construct, 
followed by splicing, should result in the production of a chimeric mRNA containing the 
TIMP-1 5’UTR and the protein coding sequence that encodes the entire CAT protein.  
These reporters were not responsive to IL-1 when tested in transfection experiments of 
astrocytes (Fig. 2.3A); however, all constructs possessed low levels of CAT activity, 





Fig. 2.3. Identification of the IL-1-responsive elements of the TIMP-1 gene.   
(A) The fragment located -4.2 to -0.8 kb upstream of the transcription start site of the 
TIMP-1 gene mediates responsiveness to IL-1.  Human astrocytes were transfected with 
reporter plasmids and a β-galactosidase expression vector. One day after transfection, cells 
were stimulated with IL-1, cultured for another 24 hours, and harvested. CAT activities 
were normalized to β-galactosidase activities to account for transfection efficiency.  
Results are expressed as fold induction relative to the plasmid phT(-0.7)CAT that contains 
700 bp long promoter of the TIMP-1 gene indicated by TP. The model of the TIMP-1 
gene, including its 5’ flanking region, is also shown (upper part of the panel); black boxes 
represent exons, restriction sites for SphI (S) and KpnI (K), and transcription start site 
(arrow) are indicated.  (B)  Detailed analysis of the -4.2 to -0.8 kb fragment of the TIMP-1 
gene. Human astrocytes were transfected with the indicated reporters and a β-galactosidase 
expression vector, and processed as described above. A model of the -4.2 to -0.8 kb 
fragment of the TIMP-1 gene is shown (upper part of the panel); putative binding sites are 
indicated, restriction sites for SphI (Sp) and SacI (S) are marked. A representative example 
of 3-6 experiments is shown.   
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transcribed and spliced, while the CAT protein synthesized was expressed in an active 
form.  Since neither the 1 kb long promoter nor the first exon and intron can mediate IL-1 
responsiveness, we cloned DNA fragments from the 5’ flanking region of the TIMP-1 gene 
in front of the 0.7 kb TIMP-1 promoter.  This approach enabled the analysis of the cloned  
DNA fragments, together with the elements specific for the TIMP-1 promoter, allowing 
any specific interactions between the IL-1-induced transcription factor(s), and the factors 
binding to the TIMP-1 promoter.  Analysis of these constructs in transient transfections 
(Fig. 2.3A) yielded one reporter containing the -4.2 to -0.8 fragment of the TIMP-1 gene 
that was responsive to IL-1. Therefore, we analyzed the shorter DNA fragments derived 
from this fragment and found that a 0.8 kb long fragment located at -2.9 to -2.1 still 
conferred responsiveness to IL-1; however, further truncations led to a decrease or loss of 
responsiveness (Fig. 2.3B). 
 
2.4.3. Identification of regulatory elements binding IL-1-induced factors.   
The entire -4.2 to -0.8 fragment of the TIMP-1 gene, which conferred IL-1 
responsiveness, was searched for the presence of putative binding sites for transcription 
factors using the Mat Inspector program (http://www.genomatix.de). We identified six 
putative binding sites, including one for AP-1, two for NF-κB, and three for ATF within 
this fragment (Fig. 2.3B and 2.4A).  Three of these elements (-2711 to -2702 NF-κB 
element,  -2174 to -2167 ATF element, and -2767 to -2761 AP-1 element) were located 
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within the 0.8 kb long fragment that conferred minimal IL-1-responsiveness (Fig. 2.3B).  
To evaluate the contribution of the six putative binding sites to the overall responsiveness 
to IL-1, we generated reporter constructs with mutations introduced into each of the 
putative regulatory sites (Fig. 2.4A).  As expected, mutations introduced into the elements 
located outside of the minimal 0.8 kb long IL-1-responsive element had no effect on the 
activity of reporters.  In contrast, mutations introduced into putative -2711 to -2702 NF-κB 
and -2174 to -2167 ATF diminished the responsiveness to IL-1, whereas mutation of the 
AP-1 element had no effect (Fig. 2.4A).  We also fused putative ATF, NF-κB, and AP-1 
elements of the TIMP-1 gene to the minimal tk promoter, which is not responsive to IL-1, 
and examined the activity of these reporters. The NF-κB element conferred IL-1 
responsiveness when linked to the tk promoter, while the AP-1 and ATF elements were 
ineffective (Fig. 2.4B).  We also noted that the intrinsic activity of the AP-1 reporter was 
greatly enhanced (Fig. 2.4B), as observed previously for other AP-1 elements (75, 109).  
We conclude that both the NF-κB and ATF elements are needed for the full response of the 
TIMP-1 gene to IL-1; however in contrast to the NF-κB element, the ATF element is 
ineffective by itself.   
These findings elucidate that both elements are binding sites for their 
corresponding transcription factors, which likely bind cooperatively to regulate TIMP-1 
gene expression.  We tested this prediction by EMSA, and observed that the ATF element 





Fig. 2.4. Identification of functional AP-1, ATF-2, and NF-κB elements within the -4.2 
to -0.8 fragment of the TIMP-1 gene.  
 Point mutations were introduced into the putative NF-κB, AP-1, and ATF elements of the 
TIMP-1 gene (A) or multiple binding elements for ATF, AP-1, and NF-κB were cloned in 
the front of tk promoter (B) as described in the Materials and Methods.  Human astrocytes 
were transfected with the indicated reporter plasmids and a β-galactosidase expression 
vector, induced with IL-1 for 24 hours, harvested, and processed as described in the legend 
to Figure 3.  Results are expressed as fold induction (A) or are shown in arbitrary units 
(untreated cells transfected with vector were set equal to 1) (B).   
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treatment of astrocytes with IL-1 induced the binding of the p65/p50 heterodimers to the 
NF-κB element (Fig. 2.5A and 2.5B).  The AP-1 element was also constitutively bound (by 
c-jun) (Fig. 2.5A and 2.5B), but this element did not mediate the IL-1 response, as shown 
by mutational analysis (Fig. 2.4A). 
 
2.4.4. Critical role of p65 in regulating TIMP-1 gene expression.   
 The IL-1 induced binding of the p65/p50 heterodimer to the -2711 to -2702 NF-κB 
element (Fig. 2.5A), and the reduced activity of the reporter lacking this element (Fig. 
2.4B) suggest that NF-κB might be the prominent factor regulating TIMP-1 expression. To 
verify this hypothesis, we used two additional NF-κB activation inhibitors CAY10470 and 
parthenolide. Both of these inhibitors abrogated the activation of TIMP-1 by IL-1 (Fig. 
2.6A). In addition, we blocked the activation of NF-κB by overexpressing the dominant-
negative inhibitor of NF-κB (IκBαSR), which is a mutated form of IκBα.  IκBαSR is not 
phosphorylated, ubiqitinated, nor degraded, and thereby effectively sequesters NF-κB (27).  
Activation of the reporter by IL-1 was substantially diminished in the presence of IκBαSR 
(Fig. 2.6B), leading us to conclude that NF-κB is critical for the IL-1-mediated expression 
of the TIMP-1 gene. The in vitro binding (Fig. 2.5A and 2.5B) suggests that the p65 
subunit of NF-κB may be critical for TIMP-1 regulation by IL-1. Therefore, we 
downregulated the expression of p65 using siRNA technology, and analyzed the response 





Fig. 2.5. AP-1, ATF-2, and NF-κB bind to the regulatory elements of TIMP-1 gene in 
human astrocytes.   
Nuclear extracts were prepared from control and IL-1 treated astrocytes as indicated. The 
binding was then analyzed by EMSA using the 32P-labeled oligonucleotide probes derived 
from the 5’ flanking region of the TIMP-1 gene (A). Specific antibodies or normal rabbit 






Fig. 2.6. Activation of p65 is indispensable for the IL-1 response of the TIMP-1 gene.  
Human astrocytes were pretreated with 1 µΜ CAY10470 or 5 µM parthenolide for 1 hour, 
and subsequently stimulated with IL-1 for 18 hours.  Expression of TIMP-1 was analyzed 
as described in the legend to Figure 2 (A).  (B)  Astrocytes were cotransfected with the 
reporter plasmid phT(-4.2-08)CAT, a β-galactosidase expression vector, and either a 
plasmid encoding the dominant-negative IκBα (pSRIκBα) or an empty vector.  CAT 
activities were assessed as described earlier (3 replicates).  (C)  Astrocytes were transfected 
with control siRNA or the SMARTpool siRNA to p65 or ATF-2, and cultured for 48 h.  
Subsequently, cells were stimulated with IL-1 for 18 h, and TIMP-1 expression was 
analyzed as described in the legend to Figure 2.2. 
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activation by IL-1 was abrogated by the p65 siRNA (Fig. 2.6C).  These results indicate that 
p65 is an indispensable component of NF-κB, which mediates the response to IL-1.  In 
contrast, the knock-down of ATF-2 expression had a dramatic effect on the TIMP-1 
expression in control and IL-1-treated cells, but the fold activation by IL-1 was not 
affected (Fig. 2.6C).  This implies that ATF-2 may regulate the intrinsic expression of 
TIMP-1. 
 
2.4.5. TIMP-1 expression is not activated by IL-1 in many gliomas due to the aberrant 
activation of either NF-κB or ATF-2.   
 Grade IV malignant gliomas (glioblastoma multiforme) are the most common 
primary brain tumors, and are characterized by extreme invasiveness, which makes 
standard treatments (including radiation and chemotherapy) ineffective.  Their invasion 
into healthy brain tissue presumably requires extensive ECM remodeling involving the 
activation of MMPs.  In primary astrocytes, the activity of the MMPs is tightly controlled 
by TIMPs, including TIMP-1, which is regulated by growth factors and cytokines, such as 
IL-1. The invasive phenotype of gliomas prompted us to hypothesize that TIMP-1 may be 
expressed at lower levels in gliomas, and IL-1 may not be able to enhance its expression. 
This would result in the increased activity of glioma-derived MMPs, and in turn would 
likely enhance the invasiveness of gliomas. In fact, we found that IL-1 did not enhance the 






Fig. 2.7. Analysis of IL-1-activated signaling and TIMP-1 expression in human 
gliomas.  (A)  U373, U251, T98G, and A172 cells were treated with IL-1 for 18 hours.  
Subsequently, RNA was isolated and subjected to Northern blot analysis using TIMP-1 
cDNA as a probe.  Lower panels show 28S RNA stained with ethidium bromide on the 
membrane.  (B)  RNA was isolated from confluent cultures of human astrocytes, U373, 
A172, T98G, and U251 cells, and expression of TIMP-1 mRNA was analyzed by real-time 
PCR.  (C-E)  Human astrocytes, U373, A172, T98G, and U251 cells were treated with IL-
1 as indicated.  Non-denaturing lysates were prepared, and analyzed by Western blotting 
with phospho-ATF-2, ATF-2, phospho-c-jun, phospho-p38, and phospho-MEK3/6 
antibodies (C), phospho-ATF-2, ATF-2, and phospho-p38 antibodies (D), and phospho-
p65 and p65 antibodies (E), and detected by enhanced chemiluminescence.   
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U251, T98G, and A172 cells (Fig. 2.7A). We also found that the intrinsic expression of 
TIMP-1 in glioma cell lines was significantly lower than in primary astrocytes (Fig. 2.7B).  
Since both ATF-2 and NF-κB regulate TIMP-1 expression in response to IL-1 in 
astrocytes, we tested whether these transcription factors are also activated in gliomas. We 
focused on ATF-2, for two reasons. First, NF-κB activation has been well documented in 
gliomas (66, 83, 111, 176, 198), and second, our prior inhibitor studies indicated that the 
inhibition of p38 (Fig. 2.2) significantly diminished the IL-1 induction of TIMP-1 in 
astrocytes. We assayed the activation of both p38 and its putative upstream kinase, 
mitogen activated protein kinase kinase (MEK)-3/6, in response to IL-1 by western 
blotting. ATF-2, MEK3/6, and p38 were rapidly phosphorylated following the IL-1 
stimulation of astrocytes (Fig. 2.7C), while neither of these proteins was phosphorylated in 
U373 glioma cells. This suggests that the IL-1/MEK3/6/p38/ATF-2 pathway is not 
functional in these cells. Surprisingly, U373 cells contain much higher levels of total ATF-
2 than astrocytes (Fig. 2.7C). The lack of ATF-2 phosphorylation seen in U373 cells in 
response to IL-1 was specific since c-jun was phosphorylated in both astrocytes and U373 
cells (Fig. 2.7C).   
Subsequently, we analyzed three additional glioma cell lines, and found that the 
MEK3/6/p38/ATF-2 pathway was not functional in A172 cells; however, ATF-2 and p38 
were efficiently activated in U251 and T98G cells (Fig. 2.7D). Although ATF-2 was 
activated in U251 by IL-1, the expression of TIMP-1 was not activated in these cells (Fig. 
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2.7D and 2.7A), suggesting that the other arm of the cooperative IL-1 response was 
ineffective.  Therefore, we examined NF-κB activation by evaluating the phosphorylation 
of p65 on serine 536, which was shown to regulate the recruitment of p300/CBP to the 
nuclear pool of p65 (217). In non-stimulated astrocytes, low levels of phosphorylated p65 
were found; however, robust phosphorylation was rapidly induced by IL-1 (Fig. 2.7E).  In 
contrast, glioma cells contain substantial amounts of phosphorylated p65, suggesting that 
NF-κB may be constitutively activated in these cells (Fig. 2.7E). This is supported because 
IL-1 induces only a slight increase in p65 phosphorylation, and hence p65 activity, in 
gliomas.  In agreement with our predictions, U251 cells contained substantially lower 
levels of p65, much of which was already phosphorylated in control cells and barely 
activated in response to IL-1.  We conclude that: i) TIMP-1 is expressed at lower levels in 
gliomas than in astrocytes, ii) TIMP-1 expression is not activated by IL-1 in most gliomas 
studied, iii) both MEK3/6/p38/ATF-2 and IKK/NF-κB are efficiently activated in response 
to IL-1 in astrocytes, iv) the gliomas studied are characterized by constitutively 
phosphorylated p65, and v) in gliomas inefficient activation of either ATF-2 or NF-κB 
correlates with the loss of IL-1 induced TIMP-1 expression. 
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2.5. DISCUSSION 
The precise control of the enzymatic activities of MMPs, in part ensured by the 
equilibrium between MMPs and TIMPs, is necessary to prevent extensive tissue damage; 
however, a temporary imbalance that favors MMPs over TIMPs is indispensable for the 
ECM remodeling that is required during many physiological processes (26, 150).  In the 
CNS, injury induces extreme acute changes in the expression pattern of both MMPs and 
TIMPs, which are necessary to initiate repair processes.  These expression profiles are 
regulated by neuroinflammatory cytokines, including IL-1.  In certain pathological states 
such as cancer, a sustained imbalance between MMPs and TIMPs may lead to the 
increased migration of cells, which may possibly aid in tumor metastasis.  In agreement 
with this, the migration of glioblastoma cells into healthy brain tissue depends upon 
increased proteolytic activity, as a prelude to ECM degradation, and subsequent invasion 
of the tumor cells.  Secreted factors control this process, with IL-1 being a likely regulator 
since it is produced by both resident brain cells and tumor cells.  Expression of TIMP-1, 
which is a highly regulated soluble inhibitor, is critical in both tissue remodeling/repair and 
invasion (78, 203).   
The expression of TIMP-1 has been shown to be transcriptionally regulated by the 
binding of multiple transcription factors including AP-1, ETS, EGR, STAT, and RUNX to 
regulatory elements present in the 5’ flanking region of the gene (15, 22, 29, 40, 49, 84).  
The binding of these transcription factors is regulated by several stimuli, including 
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cytokines and growth factors such as IL-6, OSM, epidermal growth factor, and 
transforming growth factor β.  Although, IL-1 has been previously reported to activate 
TIMP-1 expression in both astrocytes (109, 192) and orbital fibroblasts (85), the 
mechanism of TIMP-1 gene regulation remained elusive.  It has been proposed that the 
extracellular signal-regulated kinase (ERK) pathway activates TIMP-1 expression in 
response to IL-1 in orbital fibroblasts, since its activation could be blocked by a MEK 
inhibitor PD98059 (85). However, both the overexpression of dominant-negative ERK1 
and treatment with PD98059 decreased the intrinsic expression of TIMP-1, and they had a 
limited if any, effect on IL-1 induced TIMP-1 expression (85).  To expand upon these 
observations, we propose that IL-1 activates TIMP-1 expression by at least two pathways 
that lead to the activation of NF-κB and ATF-2, which bind to newly identified regulatory 
elements of the TIMP-1 gene. The activation of NF-κB by IL-1 is critical for the induction 
of TIMP-1 expression, since the presence of the IKK inhibitors (BAY11-7082, 
CAY10470, and parthenolide) (Fig. 2.2C and 2,6A) or the dominant-negative IκBαSR 
(superrepressor) (Fig. 2.6B) dramatically diminished TIMP-1 induction.  Specifically, p65 
is the component of the NF-κB that is indispensable for the induction of TIMP-1 
expression, since its downregulation abolished upregulation by IL-1 (Fig. 2.6C).  
Conversely, the activation of ATF-2 by the MEK3/6-p38 pathway is needed for the 
intrinsic expression of TIMP-1, and the response to IL-1.  These conclusions are supported 
by the following findings: i) inhibition of p38 by SB202190 significantly reduced both 
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basal expression of TIMP-1, and its activation by IL-1 (Fig. 2.2C), and ii) the knock-down 
of ATF-2 expression drastically diminished the basal and IL-1-induced levels of TIMP-1.  
It is tempting to speculate that the binding of ATF-2, which possesses histone 
acetyltransferase activity, may induce the acetylation of nearby histones, relaxation of 
chromatin, and thereby enabling the efficient binding of NF-κB.  Surprisingly, a general 
inhibitor of protein kinase C effectively blocked TIMP-1 activation by IL-1 (Fig. 2.2C).  
The experiments we report do not explain this observation, and we can only speculate that 
PKC may either be needed to phosphorylate p65 (59) or to activate proteins necessary for 
the effective NF-κB activation such as sphingosine kinase-1 (209).   
The cooperative activation of the TIMP-1 gene by IL-1 in astrocytes via activation 
of both the IKK/NF-κB and MEK3/6/p38/ATF-2 pathways partially resembles the NF-κB- 
and p38-dependent mechanism that regulates MMP-1 and MMP-3 expression in synovial 
fibroblasts (91), and the NF-κB-, C/EBP-, and ATF-2-dependent mechanism of nitric-
oxide synthase activation in rat glial cells (17).  The mechanism we propose (Fig. 2.8) for 
the regulation of TIMP-1 in astrocytes likely controls other genes in these cells, and may 
also function in other cell types.  
The newly identified ATF and NF-κB binding elements of the TIMP-1 gene likely 
bind cooperatively ATF-2 homodimers and p65/p50 heterodimers, which may be needed 





Fig. 2.8.  Model of the activation of the TIMP-1 gene in human astrocytes.  
 In astrocytes, IL-1 activates the signaling pathways that lead to the phosphorylation of 
IKK (which can be blocked by BAY11-7082, CAY10470, and parthenolide) and MEK3/6 
(both likely phosphorylated by TAK1).  Activated IKK phosphorylates IkBα, which leads 
to its subsequent ubiqutination and degradation (this can be blocked by expressing 
dominant-negative IkBα).  Liberated p65/p50 complexes translocate to the nucleus, and 
bind to the TIMP-1 regulatory element at -2.7 kb (knock down of p65 expression abrogates 
this signaling).  Concurrently, activated MEK3/6 phosphorytlates p38 kinase (this can be 
blocked by SB202190), which in turn phosphorates ATF-2 bound to its TIMP-1 regulatory 
region at -2.2 kb.  Both ATF-2 and p65/p50 complexes are needed for the full activation of 
the TIMP-1 gene expression in astrocytes. 
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findings that both of these elements are required for the full IL-1-induced transcriptional 
activity of the TIMP-1 reporter constructs harboring mutated binding elements (Fig. 2.4A).  
Furthermore, an array of ATF binding elements was not able to confer IL-1 responsiveness 
onto the minimal tk promoter, while three copies of the NF-κB element were effective 
(Fig. 2.4B). All of these results suggest that single ATF and NF-κB elements represent 
binding sites which likely cooperate to activate transcription of the TIMP-1 gene.  In 
contrast, mutation of an AP-1 element at -2.7 kb had no effect on IL-1 responsiveness (Fig. 
2.4A), but an array of the AP-1 elements dramatically increased the intrinsic activity of the 
AP-1-tk reporter (Fig. 2.4B) while having a negligible effect on the IL-1 induced activity. 
Both of these results suggest that this element may therefore be important for the intrinsic 
expression of the endogenous gene by recruiting coactivators necessary for chromatin 
modification and remodeling, which cannot be properly recapitulated using reporter 
constructs.   
Although IL-1 increases the phosphorylation of c-jun in astrocytes (Fig. 2.7), the 
ATF binding element does not bind ATF-2/c-jun heterodimers in vitro (Fig. 2.5B), but 
selectively binds homodimers of ATF-2. In contrast, c-jun effectively binds the AP-1 
element of the TIMP-1 gene (Fig. 2.5). As suggested for other genes (63), the selective 
binding of the ATF-2 homodimers may represent another level of specificity in the TIMP-
1 gene regulation. 
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IL-1 is continuously produced and regulates normal physiological processes in the 
brain. Also, the expression of IL-1 is greatly increased after brain injury and during the 
progression of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease  
(20, 146). Furthermore, IL-1 is also expressed by glioma cells and in cells surrounding 
necrotic tumors, such as glioblastoma multiforme (200). Since IL-1 enhances the 
expression of several MMPs it is tempting to propose that the net proteolytic activity 
secreted by gliomas is increased, and may be a cause of the extreme invasiveness of these 
cells. The IL-1-induced expression of TIMP-1 in astrocytes likely provides a delayed 
mechanism that limits the proteolytic activities of MMPs, which are needed in the initial 
phase following brain injury. In contrast to astrocytes, expression of TIMP-1 is not 
enhanced by IL-1 in glioma cells (Fig. 2.7A), suggesting that this “safety mechanism” to 
limit the proteolytic activities of MMPs, is not functional in gliomas. Moreover, the 
intrinsic expression of TIMP-1 in gliomas is significantly lower than in astrocytes (Fig. 
2.7B). Our data suggest that either the IKK/NF-κB or the MEK3/6/p38/ATF-2 pathway is 
dysfunctional or deregulated in gliomas (Fig. 2.7 C-E). We also noted that the intrinsic 
levels of ATF-2 were higher in gliomas than in astrocytes (Fig. 2.7C and 2.7D), but the 
importance of this observation is unclear since levels of ATF-2 did not correlate with its 
activation.   
It is important to stress that the intrinsic levels of p65 phosphorylated on serine 536 
were higher in gliomas than in astrocytes; however, the IL-induced increase in this 
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phosphorylation was much lower in gliomas. These results suggest that NF-κB may be 
continuously activated in gliomas, which is of fundamental importance. Recently, the link 
between carcinogenesis and inflammation has become evident (reviewed in (108)), and 
NF-κB is proposed to be critical for tumor promotion and progression. Activated NF-κB 
may therefore provide signals that allow gliomas to evade apoptosis, and increase; 
angiogenesis, self-sufficiency in growth, insensitivity to growth inhibition, and to gain 
limitless replicative and invasive potential (55, 108). It remains to be established if the 
decreased IL-1-induced phosphorylation of p65 on serine 536 correlates with these tumor 
promoting processes. Furthermore, the precise role of this modification needs to be 
addressed, since it was recently shown that it defines an IκBα-independent pathway of NF-
κB activation (178), and results in accelerated NF-κB turnover (126). 
In summary, we propose a novel mechanism of TIMP-1 activation by IL-1 in 
human astrocytes, which involves the activation of two signaling pathways; IKK/NF-κB 
and MEK3/6/p38/ATF-2. Activated NF-κB and ATF-2 bind to novel regulatory elements 
at -2.7 kb and -2.2 kb, and activate the transcription of TIMP-1. In contrast to astrocytes, 
this mechanism does not properly function in glioma cell lines due to the defective 
activation of at least one of these pathways. Lack of enhanced TIMP-1 expression in 
gliomas may, in part, explain their increased invasiveness.  
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CHAPTER 3  




Recently, inflammatory processes have been implicated in the development and 
progression of various tumors. Here, we investigated whether inflammation is associated 
with the growth of oligodendroglioma tumors. We analyzed the expression of major pro-
inflammatory cytokines and chemokines, including IL-1, TNFα, IL-6, OSM, IL-8, MCP1, 
MIP1α, and MIP1β in the clinical samples of patients suffering from oligodendroglioma 
(OD). We found that OSM, IL-6, MCP1, MIP1α, and MIP1β expression levels were 
significantly higher in the OD samples, when compared to normal cortical brain tissue, 
thus contributing to the generation of an inflammatory milieu within the tumors. In 
addition, we investigated if oligodendroglioma and schwannoma cells produced these 
inflammatory mediators in vitro. Indeed, these cells express the same set of cytokines in 
vitro upon IL-1 induction. Consistent with the cytokine expression pattern, we found that 
both STAT3 and NF-κB, are efficiently activated in oligodendroglioma and schwannoma 
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cells upon OSM and IL-1 stimulation, respectively. However, STAT3, but not NF-κB, is 
highly activated in the OD samples. Moreover, OSM, but not IL-1 promoted cell 
proliferation in vitro and this effect was mediated through STAT3. Indeed, 
pharmacological inhibition of STAT3 phosphorylation, a knock-down of STAT3 with 
shRNA, or dominant negative STAT3 abolished the proliferative effect of OSM. In 
addition, we analyzed the expression of inflammation-induced alpha-1-anti-chymotrypsin 
(ACT), which is STAT3-dependent. Our data indicate that ACT is present at elevated 
levels in patient samples and is also upregulated by OSM and IL-1 in oligodendroglioma 
and schwannoma cells. In summary, oligodendroglioma tumors secrete and respond to 
inflammatory mediators, with OSM being the major cytokine that activates STAT3 to 




Recently, it was established that inflammation promotes cancer (44). Normal 
inflammation is a self-limiting process, as it is followed by an anti-inflammatory response 
leading to the resolution phase and a return to normal homeostasis. However, persistent 
and excessive action of pro-inflammatory stimuli, and failure to resolve the inflammatory 
response, can lead to a chronic inflammatory state, which is the main driving force of 
anaplastic progression (129). In fact, there are many examples of chronic inflammatory 
diseases that lead to cancer. The strongest evidence comes from colon cancer, which is 
associated with inflammatory bowel diseases. Furthermore, infection with the virus 
hepatitis C predisposes patients to liver carcinoma, schistosomiasis increases the risk of 
bladder and colon cancers, and Helicobacter pylori is a well established carcinogen in 
gastric cancer (129).  
Inflammation is also a primary response of the brain to injury or infection. It has 
been implicated in multiple neurodegenerative disorders, such as AD, PD, stroke, 
depression, schizophrenia, epilepsy, MS, and traumatic brain injury (134). A chronic 
inflammatory state also develops within the necrotic center of glioblastoma, the most 
malignant glial tumor of the brain (200). Interleukin-1 (IL-1), Interleukin-6 (IL-6), and 
Tumor Necrosis Factor α (TNFα) are the most prominent cytokines involved in these brain 
inflammatory processes. IL-1 and TNFα exert their effects through the activation of NF-
κB, which regulates the expression of genes involved in suppression of tumor cell death, 
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tumor cell cycle progression, and promotion of tumor invasiveness, angiogenesis, and 
metastasis (76, 204). On the other hand, the IL-6 family of cytokines, including IL-6 and 
OSM, activates the JAK-STAT signaling pathway, which predominantly regulates 
malignant cell proliferation and survival by targeting genes promoting cell cycle 
progression and suppression of apoptosis (24, 25). IL-6 is a key growth-promoting and 
anti-apoptotic cytokine, whereas OSM has both pro- and anti- inflammatory actions (194). 
OSM is not detected in the normal brain; however, it is expressed in activated microglia, 
hypertrophic astrocytes and infiltrating leukocytes in the brains of patients with MS and 
HAD (37). Increased levels of OSM have also been detected in brain tumors, including 
astroglioma, glioblastoma multiforme, and pituitary adenoma. Nevertheless, the role of 
OSM in the development and progression of other brain tumors has not been described.  
Oligodendroglioma (OD) is the third most common glial neoplasm, accounting for 
2-5% of all primary brain tumors. According to the current WHO guidelines, it can be 
classified as a well-differentiated grade II oligodendroglioma, or a grade III anaplastic 
oligodendroglioma (112). Most oligodendrogliomas manifest in adults in their 40-50s with 
the vast majority of tumors occurring in the frontal, temporal, parietal, and occipital lobes. 
Surgical resection is the mainstay of initial treatment, which is followed by chemotherapy 
(113). Significantly, 70% of oligodendrogliomas with a loss of chromosome regions 1p 
and 19q respond favorably to this treatment, thus increasing the survival rates. The median 
postoperative survival period for patients with grade II oligodendroglioma ranges from 3-
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17 years. However, the median survival time ranges from 10 months to 3.9 years for 
patients with anaplastic oligodendroglioma, receiving surgical and radiotherapy treatments 
(201). Nevertheless, every patient diagnosed with oligodendroglioma will eventually die of 
this disease. Despite progress in the treatment of oligodendrogliomas, molecular markers 
of these tumors are still not well characterized in contrast to the markers of glioblastomas. 
Therefore, defining the molecular differences and similarities between these two, most 
common glial tumors of the brain is critical.  
It is unclear whether inflammation is associated with, and contributes to the 
development and progression of brain tumors. Thus far, inflammatory cytokines such as 
IL-1 and IL-6 were detected in malignant gliomas (166, 200), specifically glioblastoma 
multiforme. Moreover, signaling pathways activating STAT3 and NF-κB are constitutively 
active within these tumors (187). Nevertheless, neither inflammatory cytokines nor 
signaling pathways were shown to play a role in the development and progression of 
oligodendroglioma tumors. Therefore, we analyzed the expression of several pro-
inflammatory cytokines, including IL-1, IL-6, OSM, and TNFα, the activation of STAT3 
and NF-κB, and expression of inflammatory markers in both the clinical samples and 
established cell lines.  
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3.3. MATERIALS AND METHODS 
 
3.3.1. Cell culture. Human oligodendroglioma HOG cells were kindly provided by Dr. 
Carmen Sato-Bigbee (Virginia Commonwealth University, Richmond, VA), while human 
schwannoma T265 cells were obtained from Dr. George H. de Vries (Loyola University 
Medical Center, Maywood, IL). Cells were cultured in Dulbecco's modified Eagle's 
medium supplemented with 10% fetal calf serum, containing penicillin/streptomycin, 
sodium pyruvate, and non-essential amino acids in a humidified 5% CO2 incubator at 37 
˚C. 
 
3.3.2. Clinical samples. Biopsy samples of human brain tissue from patients with 
oligodendroglioma tumors were obtained from VCU’s brain tumor bank (Department of 
Neurosurgery, Virginia Commonwealth University, Richmond, VA). Normal cortical 
tissue samples were obtained from a healthy brain region of a patient with OD or epileptic 
patients. Brain tissue biopsies were snap-frozen and subsequently homogenized in liquid 
nitrogen for total RNA and protein preparation. The biopsy samples we analyzed represent 
primary oligodendroglioma tumors, grade II and III, as well as the recurrent tumors. All 
tested samples expressed significant amounts of the myelin basic protein MBP (data not 
shown), which is the oligodendrocyte marker, thus confirming the oligodendroglial origin 
of these tumors. 
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3.3.3. Cytokines and cell stimulation. Cells were stimulated with 10 ng/ml IL-1 (a gift 
from Immunex Corp., Seattle, WA, USA), 25 ng/ml OSM, or 5 ng/ml TNFα (both from 
R&D, Systems, Inc., Minneapolis, MN, USA). One µM dexamethasone (Sigma Chemical 
Co., St. Louis, MO, USA) was also added to enhance cytokine action for the analysis of 
ACT expression, 100 µM AG490 (Calbiochem, Darmstadt, Germany) was added 1 hour 
prior to cytokine stimulation.  
 
3.3.4. RNA preparation and quantitative PCR. Homogenized brain tissue, or cultured 
cells were lysed by Trizol (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions to prepare total RNA. Target gene mRNA levels were measured using 
TaqMan technology (Applied Biosystems, Foster City, CA) according to the supplier’s 
instructions. Briefly, 1 µg of total RNA was reverse-transcribed using the High capacity 
cDNA archive kit. Subsequently, the cDNAs were diluted 10-fold (for target genes) or 
100-fold for GAPDH, and amplified using TaqMan pre-mixed primer-probe sets, 
Universal PCR Master Mix, and ABI 7900HT cycler. 
 
3.3.5. Plasmids and transient or stable transfections.  Plasmids containing the ACT 
promoter (pACT-361CAT, pdmACTCAT), and ACT enhancer (p∆5ACTCAT, 
p(muttriple)ACTCAT)  were described previously (115). Cells were transiently transfected 
in 12 well clusters by FuGENE6 transfection reagent (Roche, Indianapolis, IN) according 
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to the supplier’s instructions. Four hundred ng of the reporter CAT plasmid, and 100 ng of 
the expression plasmid encoding β-galactosidase were used per well. One day after 
transfection, cells were stimulated with cytokines, cultured another 24 hours, and 
harvested. Protein extracts were prepared by freeze thawing, and chloramphenicol 
acetyltransferase (CAT) and β-galactosidase activities were assayed as described (117). An 
expression plasmid containing the dominant negative STAT3 (STAT3-DN) (109) was co-
transfected with a pcDNA3 plasmid carrying the neomycin resistance gene into HOG cells. 
Briefly, 4.5 µg STAT3-DN and 0.5 µg pcDNA3 were incubated with 15 µl FuGENE6, and 
transfected into a 10 cm dish of 30% confluent HOG cells. The next day, 10% FBS 
DMEM containing 1 mg/ml G418 (Hyclone, Logan, UT) was added, and it was replaced 
every day for 2 consecutive weeks to generate stable HOG/STAT3-DN clones that were 
later pooled. 
  
3.3.6. Western blotting.  Homogenized brain tissue was lysed in 2% SDS, 50 mM Tris pH 
7.5, and 1 mM sodium orthovanadate at 90°C. Cultured cells were lysed in 10 mM Tris pH 
7.4, 150 mM sodium chloride, 1 mM EDTA, 0.5% NP-40, 1% Triton X-100, 1 mM 
sodium orthovanadate, and 0.4 mM PMSF. Subsequently, the protein concentration was 
determined by the BCA method (Sigma Chemical Co., St. Louis, MO), equal amounts 
were resolved using SDS-PAGE, and electroblotted onto nitrocellulose membrane 
(Schleicher & Schuell, Keene, NH).  Polyclonal, anti-p65, anti-PARP-1, and anti-β-tubulin 
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antisera were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), while 
anti-phospho-p65, and anti-phospho-IkBα were purchased from Cell Signaling 
Technology, Inc. (Beverly, MA). Monoclonal anti-phospho-STAT3, anti-STAT3, anti-
phospho-STAT1, anti-STAT1, anti-phospho-STAT5, and anti-STAT5 antibodies were a 
gift from Dr. Andrew Larner (Massey Cancer Center, Virginia Commonwealth University, 
Richmond, VA). Polyclonal anti-COX-2 antibody was a gift from Dr. Frank Fang 
(Department of Biochemistry, Virginia Commonwealth University, Richmond, VA). 
Antigen-antibody complexes were visualized by enhanced chemiluminescence according 
to the manufacturer’s instructions (Pierce, Rockford, IL). Densitometry analysis was 
performed as indicated using the NIH Image J software. 
 
3.3.7. Gene knockdown by siRNA.  RelA (p65) expression was down-regulated using 
SmartPool siRNAs and Dharmafect 1 transfection reagent (both from Dharmacon, Inc. 
Lafayette, CO) according to the suggested manufacturer’s protocols. The efficiency of the 
gene knockdown was assayed by Western blotting 48 hours post-transfection.   
 
3.3.8. Cell proliferation assay. Cells were grown in 24-well plates in 10% FBS DMEM, 
and then stimulated with cytokines in the presence of 1 µCi/ml [methyl-3H]-thymidine 
(Amersham, UK). Twenty four hours later, cells were washed 3 times with PBS, and DNA 
was precipitated with ice-cold 20% trichloroacetic acid (TCA) solution for 30 min on ice. 
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This was followed by 3 washes with 5% TCA, and solubilization by 70% formic acid for 1 
hour at 37 °C. Cell lysates were then analyzed for radioactivity content in a scintillation 
counter. Independent experiments were repeated at least twice, and data were presented as 
a percentage of proliferation versus non-treated cells. Alternatively, the WST-1 reagent 
(Roche, Indianapolis, IN) was used to measure cell proliferation. Briefly, cells grown in 
10% FBS DMEM were treated with cytokines for 24 h. Next, the cells were incubated with 
WST-1 for 30 minutes at 37 °C in a humidified 5% CO2 atmosphere. Absorbance of the 
reaction product was measured at 450 nm with background subtraction at 630 nm. All 
experimental points were performed in triplicates and independent experiments were 
repeated at least twice. Statistical analysis was performed by one-way analysis of variance. 
Differences were considered statistically significant when p-values were <0.05.  
 
3.3.9. Lentiviral transductions of HOG cells. Lentiviral stock containing the packaged 
GFP-labeled non-targeting shRNA expression construct (Invitrogen, Carlsbad, CA) was a 
gift from Dr. Frank Fang (Department of Biochemistry, VCU). Lentiviral vector 
containing GFP-labeled STAT3-targeting shRNA was a gift from Dr. Andrew Larner 
(VCU Massey Cancer Center, Richmond, VA) and was described previously (92). These 
shRNA-expressing lentiviral constructs were packaged in 293FT cells according to the 
supplier’s instructions (Invitrogen, Carlsbad, CA). Subsequently, HOG cells were 
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incubated with the produced lentiviruses for 48 hours, which resulted in 30-50% 
transduction efficiency, estimated by a visual analysis of cells with GFP fluorescence. 
These cells were then expanded, and GFP+ cells were selected by cell sorting (Flow 
Cytometry and Imaging Shared Resource Facility, VCU) and used for further experiments. 
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3.4. RESULTS 
3.4.1. Pro-inflammatory cytokine genes are highly expressed in the 
oligodendroglioma tumors.   
Inflammatory processes have been implicated in the development and progression of 
various tumors. These tumors secrete a plethora of cytokines, and are characterized by the 
activation of cytokine-induced pathways (129). Thus far, neither the expression of 
inflammatory cytokines nor the activation of corresponding signaling pathways has been 
investigated in oligodendrogliomas. Therefore, we have analyzed cytokine expression in 
the samples of patients suffering from these tumors. Since IL-1, TNFα, IL-6, and OSM 
have been shown to regulate inflammation in the CNS (37, 204), we investigated the 
expression levels of these cytokine genes in the OD samples, and compared them to 
normal cortical tissue (Fig. 3.1A). We found that OSM and IL-6 mRNA was expressed at 
higher levels in most of the OD patients, while IL-1 mRNA was elevated in half of the 
samples. Our data suggest that OSM and IL-6, which both belong to the same cytokine 
family, may trigger a local inflammatory response in OD patients. In contrast, the 
expression of TNFα was not significantly changed in most of the patient samples. 
Moreover, chemokines are crucial for the local inflammatory response, as they recruit and 
activate immune cells. Specifically, IL-8 acts as a chemoattractant and activator of 
neutrophils (8), MCP1 acts primarily on macrophages (215), and MIP1α and MIP1β have 





Fig. 3.1. Pro-inflammatory cytokine genes are highly expressed in oligodendroglioma 
tumors. Biopsy samples of oligodendroglioma tumors (OD; ) from 12 different, patients 
and 3 control samples of healthy brain tissue (normal; •) were homogenized and processed 
for RNA isolation. Subsequently, expression of cytokines (A) and chemokines (B) was 
assayed by qPCR, and normalized to GAPDH levels. Data were analyzed in triplicates, and 
are represented as a fold change in reference to normal cortical tissue. A mean value was 
calculated for each group, and is represented by the black bars.   
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demonstrate that MCP1 mRNA expression levels were strikingly elevated in most of the 
OD patients, whereas MIP1α and MIP1β mRNA were increased in half of the OD samples 
when compared to the normal cortical tissue. However, IL-8 mRNA amounts were not 
significantly increased in most OD samples. According to our data, chemokines attracting 
macrophages, but not neutrophils, are elevated in OD samples, suggesting that 
macrophages may play a pivotal role over neutrophils in the local inflammation within the 
oligodendroglioma tumors.  
In this study, eight samples were from primary oligodendroglioma grade II and III 
tumors, whereas four samples represented recurrent oligodendrogliomas. There was no 
correlation between expression of the pro-inflammatory cytokines/chemokines and the 
oligodendroglioma grade. We conclude that oligodendroglioma tumors show increased 
expression of select pro-inflammatory cytokines, mainly OSM, IL-6, MCP1, MIP1α, and 
MIP1β, that likely drive a local inflammatory reaction within the tumor, which is 
independent of the tumor grade.  
 
3.4.2. Oligodendroglioma HOG and schwannoma T265 cells express pro-
inflammatory cytokines and chemokines.   
The biopsy samples consist of blood and other brain cells, apart from 
oligodendroglioma cells, thus analyzing the cytokine expression pattern does not specify 





Fig. 3.2.  IL-1 induces the expression of pro-inflammatory cytokines and chemokines 
in oligodendroglioma and schwannoma cells.  Both HOG and T265 cells were 
stimulated with IL-1 for the indicated times, and RNA was prepared. Subsequently, IL-1, 
IL-6, OSM (A, B), MCP1 (C, D), MIP1α and MIP1β (Ε) mRNA levels were assayed by 
qPCR and normalized to GAPDH. Data were analyzed in triplicates, and are represented as 
a fold induction in reference to the untreated sample.  
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HOG cell line, and we tested its capability to produce cytokines in response to IL-1, which 
is a major neuro-inflammatory cytokine. In fact, IL-1 activated the expression of IL-6, and 
itself (Fig. 3.2A). Interestingly, these cytokine mRNAs peaked at 2-4 hours, which 
indicates a rapid and time-sensitive induction of response to inflammatory stimuli. For 
comparison, we analyzed the cytokine expression pattern in T265 cells, which derive from 
schwannoma tumor localized to peripheral nerve myelin sheaths. Since Schwann cells 
serve as a functional equivalent of oligodendrocytes in the peripheral nervous system, we 
anticipated that these cells will also produce similar cytokines as HOG cells. Indeed, T265 
cells produced IL-1 and IL-6 upon IL-1 stimulation (Fig. 3.2B). Interestingly, neither HOG 
nor T265 cells expressed OSM upon IL-1, OSM, or PGE2 stimulation (data not shown). 
Subsequently, we analyzed the expression of chemokines in both HOG and T265 cells. 
MCP1 was robustly induced in both cell types (Fig. 3.2C-D). However, MIP1α and MIP1β 
were drastically induced in T265 cells, but not in HOG cells (Fig. 3.2E). Altogether, these 
data suggest that cytokines detected in the OD samples, such as IL-6, MCP1, and IL-1, but 
not OSM, may derive from oligodendroglioma cells as they are capable of producing these 
cytokines in vitro. 
 
3.4.3. ACT and COX-2 as inflammatory markers in OD tumors.  
Inflammation induces the expression of a plethora of effector genes, which are 





Fig. 3.3. Oligodendroglioma tumors and cells express ACT and COX-2. Expression of 
ACT mRNA was analyzed by qPCR, and normalized to GAPDH following RNA isolation. 
(A) Biopsy samples of oligodendroglioma tumors (OD; ) from 12 different patients, and 
3 control samples of the healthy brain tissue (normal; •) were processed as in Fig. 1. A 
mean value was calculated for each group, and is represented by the black bars. (B) RNA 
was prepared from untreated primary human astrocytes (Astr), U373, HOG, and T265 
cells. qPCR assays were performed from three independent cultures, and data were 
analyzed in duplicates. ACT expression level in primary human astrocytes was set to 1. 
(C) HOG and T265 cells were stimulated with IL-1 or OSM for 18 h. One µM 
Dexamethasone was added to enhance cytokine action. Data are presented as a fold 
induction in reference to the untreated sample. Experiments were performed three times. 
(D) Biopsy samples of OD tumors were homogenized and protein lysates were prepared. 
Protein levels of COX-2 and β-tubulin were detected by Western blotting. Patient clinical 
number is indicated by # (#1226 is the normal cortical tissue).   
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is produced by activated hepatocytes in the liver (31), and by reactive astrocytes in the 
brain (2), in response to ongoing inflammation. Therefore, we analyzed its expression in 
the OD samples, and we found high expression levels of ACT mRNA (Fig. 3.3A). In order 
to specify the cell type expressing ACT in the OD samples, we analyzed the expression of 
ACT in the established oligodendroglioma and schwannoma cell lines. These cells were 
compared to astrocytes and glioblastoma cells, which are known sources of ACT in the 
normal and pathological brain. Surprisingly, intrinsic ACT expression levels are 100-fold 
lower in HOG and T265 cells than in astrocytes or glioblastoma U373 cells (Fig. 3.3B). 
However, ACT expression was strongly activated by both IL-1 and OSM, resulting in a 
200-500 fold increase in HOG and T265 cells (Fig. 3.3C).  
Since enhanced COX-2 immunoreactivity has been reported in the OD tumor 
microenvironment (28), we analyzed the expression of COX-2 in OD samples (#1323, 
#1330, #1129, #1173, #1260), which contained high levels of IL-1, IL-6, and OSM (Fig. 
3.3D). Indeed, these samples were also characterized by the increased COX-2 levels when 
compared to normal cortical tissue (#1226); however, COX-2 was not induced in HOG 
cells by IL-1, OSM, or PGE2 (data not shown). Thus, COX-2 is likely produced by 
immune cells, (i.e. the macrophages) that are recruited to the site of inflammation.    
Collectively, these data suggest that inflammation induces the expression of 





Fig. 3.4. NF-κB and STAT3 regulate ACT expression in oligodendroglioma and 
schwannoma cells. HOG (A) or T265 (B) cells were transfected with either control or p65 
siRNA. 48 h post-transfection, cells were stimulated with IL-1 for 18 h in the presence of 1 
µM Dexamethasone. RNA was extracted and reverse-transcribed. ACT mRNA was 
quantified by qPCR and normalized to endogenous GAPDH mRNA. Experiments were 
repeated three times in duplicates. (C) The efficiency of p65 down-regulation was assessed 
by Western blotting 48 h post-transfection, and β-tubulin was used as a loading control. 
(D) T265 cells were transfected with ACT promoter, ACT enhancer reporters, and a β-
galactosidase expression vector. 24h after transfection, cells were stimulated with IL-1 or 
OSM, cultured for another 24 h, and harvested. CAT activities were normalized to β-
galactosidase activities to account for transfection efficiency. Results are expressed as fold 
induction relative to the untreated sample for each plasmid. The experiments were repeated 
three times. The model of the ACT gene, including its 5’ flanking region, is also shown in 
the upper part of the panel; black boxes represent exons, transcription factors binding sites 




addition, these data also demonstrate that brain cells, other than of astrocytic origin, can 
express ACT, which is further increased by cytokine stimulation. 
 
3.4.4. NF-κB and STAT3 regulate ACT expression in oligodendroglioma HOG and 
schwannoma T265 cells. 
In the brain, ACT expression is increased by inflammatory cytokines in astrocytes 
and glioblastoma cells (116, 117). This induction of ACT expression is mediated by the 
activation of NF-κB and STAT3; however, the mechanisms regulating the ACT expression 
in oligodendroglioma and schwannoma cells are not known. Therefore, we down-regulated 
the p65 subunit of NF-κB in these cells, and examined the ACT gene activation by IL-1 
stimulation (Fig. 3.4A-B). In fact, IL-1 could no longer stimulate ACT gene expression in 
cells depleted of p65 (Fig. 3.4B-C). The ACT gene contains two STAT3 binding sites 
within its promoter, and two NF-κB binding sites within the -13 kb enhancer, which in 
primary human astrocytes mediate ACT activation in response to OSM and IL-1, 
respectively (116, 117). In order to verify that these regulatory elements function in 
oligodendroglioma/schwannoma cells, we used several ACT reporters in transient 
transfection experiments of T265 cells, as HOG cells are very difficult to transfect. Thus, 
we transiently transfected reporters containing either the ACT promoter, or the ACT 
enhancer and promoter, and analyzed the reporter activity after OSM and IL-1 stimulation 
(Fig. 3.4D). Indeed, OSM strongly activated these reporters, and this activation was 
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abolished when the two STAT3 binding sites were mutated. In contrast, IL-1 only 
activated the reporter containing the ACT enhancer, and this activation depended on the 
two NF-κB binding sites. Altogether, these results provide strong evidence that ACT 
expression is regulated by NF-κB and STAT3 in oligodendroglioma and schwannoma cells 
upon IL-1 and OSM stimulation, which parallels its regulation in primary human 
astrocytes and glioblastoma cells. 
 
3.4.5. Constitutive activation of STAT3 in oligodendroglioma. 
The presence of inflammatory cytokines in OD samples suggests that 
corresponding inflammatory signaling pathways may be activated. Cytokines of the IL-6 
family, including IL-6 and OSM, activate the JAK-STAT pathway, which is constitutively 
active in multiple cancers, with STAT3 being a well-known oncogene (93). Therefore, we 
assessed the phosphorylation of STAT3 (Fig. 3.5A) in the OD samples expressing high 
levels of OSM, IL-6, and IL-1. In all of these samples we detected significantly higher 
levels of phosphorylation of STAT3 on Tyr705, a modification, which is necessary for 
STAT3 dimerization and nuclear translocation. However, control samples (n=3, only 
#1226 shown in Fig. 3.5A) had only a background phosphorylation level of STAT3. The 
densitometric analysis indicated that the levels of phosphorylated STAT3 (Tyr 705) were 
64-1000 fold higher in the OD samples than in normal brain. In addition, OSM induced 





Fig. 3.5. STAT3 is activated in oligodendroglioma. Biopsy samples of OD tumors were 
homogenized and denaturing protein lysates were prepared (A, C, E). Patient clinical 
number is indicated by # (#1226 is the normal brain cortical tissue). Densitometry analysis 
indicated an increase (64-1000 fold) in phospho-STAT3 in OD samples relatively to 
normal brain. (B, D, F) HOG and T265 cells were stimulated with OSM for 30 min or with 
IL-1 for the indicated times, cell lysates prepared, and protein levels of phospho-STAT3, 
STAT3, phospho-STAT1, STAT1, STAT5, phospho-p65, p65, phospho-IκBα, and β-
tubulin were detected by Western blotting. Experiments were repeated in duplicates.  
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On the contrary, phosphorylation of STAT3 on Ser727 was not increased in OD samples, 
nor induced by OSM in HOG cells (data not shown). Interestingly enough, neither the 
phosphorylation of STAT1 on Tyr701 nor STAT5 on Tyr694 (Fig. 3.5C and data not 
shown) were substantially different between normal and OD samples. In vitro, STAT1 was 
phosphorylated on Tyr701 by OSM in HOG cells (Fig. 3.5D); however, STAT5 was not 
affected.  
The activation of NF-κB was assessed in the OD samples characterized by high 
expression levels of IL-1 (Fig. 3.5E). We analyzed phosphorylation of p65 in these 
samples, but no correlation was found. In contrast, in vitro stimulation of HOG and T265 
cells by IL-1 (Fig. 3.5F) resulted in robust phosphorylation of IκBα and p65 on Ser536. 
These findings indicate that both STAT3 and NF-κB are efficiently activated in 
oligodendroglioma and schwannoma cell lines, upon OSM and IL-1 stimulation, 
respectively. Moreover, STAT3 is activated in oligodendroglioma tumors, which strongly 
supports the importance of the JAK-STAT pathway in these tumors. 
 
3.4.6. Effect of pro-inflammatory cytokines on proliferation and apoptosis of 
oligodendroglioma HOG cells.   
Inflammatory milieu within a tumor may be generated by both the tumor cells 
themselves, surrounding activated normal cells, and extravasating immune cells (129). 





Fig. 3.6. Pro-inflammatory cytokines affect proliferation and apoptosis of 
oligodendroglioma cells.  (A) HOG cells were stimulated with IL-1, OSM, IL-6, or TNFα 
as indicated. After 24 h [methyl-3H]-Thymidine incorporation proliferation assay was 
performed as described in the M&M section. Experiments were performed twice, with 
experimental points repeated 3-4 times. Data are represented as a percentage of 
proliferation in reference to the untreated cells. Error bars are standard deviations and 
p<0.01 (B) HOG cells were stimulated with IL-1 or TNFα for 8 or 24 h as indicated. Cell 
lysates were prepared, and PARP-1 and β-tubulin were detected by Western blotting.  
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OSM, IL-6, and TNFα, we assessed whether these cytokines affect oligodendroglioma 
tumor growth. We found that OSM increased the proliferation of HOG cells by 50-60 % 
within 24 hours (Fig. 3.6A). IL-6 also had a moderate proliferative effect of 20%, whereas 
neither IL-1 nor TNFα were effective. Moreover, we measured PARP-1 cleavage after IL-
1 and TNFα stimulation, which is an indicator of ongoing apoptosis (Fig. 3.6B). TNFα 
induced partial PARP-1 cleavage, while IL-1 had no effect. We conclude that OSM and 
IL-6 promote oligodendroglioma cell proliferation, whereas TNFα may be deleterious, as 
it induces the apoptosis of oligodendroglioma cells. 
 
3.4.7. Activated STAT3 enhances the proliferation of HOG cells. 
Constitutively activated STAT3 is present in multiple cancers, and contributes to 
their progression through stimulating the proliferation of tumor cells, and suppressing the 
anti-tumor immune response (212). Since OSM and IL-6 stimulate the proliferation of 
oligodendroglioma cells, we tested whether this effect is mediated through STAT3. We 
used AG490, a Jak2 inhibitor previously shown to inhibit STAT3 phosphorylation (166). 
Indeed, OSM could no longer increase proliferation of HOG cells in the presence of the 
inhibitor (Fig. 3.7A). To verify these data, we knocked-down the STAT3 expression with 
an shRNA-expressing lentiviral vector (Fig. 3.7D). Significantly, expression of shRNA to 
STAT3, but not control shRNA, abolished the proliferative effect of OSM in HOG cells 





Fig. 3.7. OSM-activated STAT3 regulates the proliferation of HOG cells. (A) HOG 
cells were pretreated with AG490 for 1 h as indicated, and then stimulated with OSM for 
24 h. (B) HOG cells were infected with lentiviral vectors encoding either a non-targeting 
control (shCON), or targeting STAT3 (shStat3) shRNA and GFP. The homogenous 
populations of GFP+ cells were then isolated by cell sorting. HOG cells expressing 
dominant negative STAT3 (STAT3-DN) were a population of pooled clones. Cells were 
stimulated with OSM for 24 h, and their proliferation was measured using [methyl-3H]-
Thymidine as described in the M&M section. Experiments were performed twice, with 
experimental points repeated 3-4 times. Data are represented as a percentage of 
proliferation in reference to the untreated cells.  Error bars represent the standard deviation 
and p<0.01. (C) HOG cells were stimulated with OSM for 18 h, RNA was isolated, and 
Myc expression was analyzed by qPCR in triplicates. Results were normalized to GAPDH, 
and are represented as a fold induction to the untreated cells; error bars indicate standard 
deviation. (D) Cell lysates were prepared from stable HOG clones described in (B), and 
analyzed for protein levels of STAT3 and β-tubulin by Western blotting.  
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negative STAT3 (STAT3-DN). These cells also do not increase their proliferation in 
response to OSM. Since STAT3 is known to affect proliferation via activation of several 
growth promoting genes, including Myc, we analyzed Myc expression after OSM 
stimulation. Significantly, Myc mRNA levels increased 2-fold after OSM stimulation, 
whereas IL-1 had no effect (Fig. 3.7B). These data demonstrate that STAT3 mediates the 
stimulatory effect of OSM on the proliferation of oligodendroglioma cells. These data are 
also consistent with the increased STAT3 phosphorylation in OD samples (Fig. 3.5A). 
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3.5. DISCUSSION 
Development and progression of cancer depends on cellular transformation, 
deregulation of apoptosis, and uncontrollable cell proliferation, accompanied by 
angiogenesis, invasion, and metastasis. Recent studies have suggested that chronic 
inflammation contributes to tumor initiation, promotion, and progression (44, 129). Indeed, 
chronic inflammation leads to the generation of a tumor-supporting microenvironment, 
which is rich in inflammatory cells, cytokines, growth and survival factors, and facilitates 
genomic instability, as well as promotes angiogenesis. Furthermore, mediators produced 
by inflammatory cells regulate the growth of both neoplastic and normal cells, including 
fibroblasts, and endothelial cells. Later during tumor progression, neoplastic cells divert 
inflammatory mechanisms to favor their growth and development, and subvert anti-tumor 
immune cell functions. However, only recently, inflammation has been associated with 
pathological processes of the brain (94, 134, 204). Thus far, inflammatory cytokines, such 
as IL-1 and IL-6, have been detected in malignant glioma tissue and activated microglia. 
Moreover, tumor-associated macrophages (TAMs) were found in the brain tumor 
microenvironment. 
 Here we report that inflammatory mediators, including IL-1, IL-6, OSM, MCP-1, 
and MIP1α/β, but not TNFα or IL-8, are present within human oligodendroglioma tumors. 
High expression levels of these mediators indicate a local inflammatory response, with a 
prevalence of cytokines of the IL-6 family, as well as macrophage/microglia activating 
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chemokines. MCP-1 is known to recruit and activate macrophages (215), and in fact, the 
presence of both macrophages and microglia have been reported previously within 
oligodedroglioma tumors (50). In addition, various immune cells may be recruited and 
activated by MIP-1α/β (142), which is upregulated in over half of the OD samples. 
However, expression of IL-8, which recruits and activates neutrophils (8), was not elevated 
in OD samples. Thus, we conclude that macrophages and microglia play a major role in 
ongoing inflammation within the OD tumors. Interestingly, these immune cells are not the 
only source of pro-inflammatory cytokines within the OD tumors. Human 
oligodendroglioma cells also produce IL-1, IL-6, and MCP-1 upon the action of IL-1 (Fig. 
3.2A-C). In contrast, cells of monocyte origin, including macrophages and microglia, are 
likely the source of OSM within OD tumors, as HOG cells do not express OSM upon 
activation by its known stimuli. According to the published data, microglia and 
macrophages in the OD tumors may secrete OSM in response to PGE2 (168), which is the 
product of COX-2. In fact, COX-2 expression is induced by IL-1 and TNFα (45), and is 
also abundant in the OD tumors (Fig.3.3).  
Our data suggest that cytokines of the IL-6 family, in particular OSM and IL-6, 
play a critical role in the etiology of OD tumors. Increased levels of OSM have also been 
found in other brain tumors, but its role is ambiguous since it can exert both growth 
promoting and inhibitory effects (37). For example, OSM inhibits the growth of human 
glioma cells in vitro, and tumor formation in vivo. On the other hand, it stimulates the 
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expression of VEGF, and hence it is pro-angiogenic and promotes glioma progression. We 
demonstrate that OSM is expressed at high levels in OD samples (Fig. 3.1A), and increases 
the proliferation of human oligodendroglioma cells (Fig. 3.6A). In addition to OSM, IL-6 
mRNA was also present in OD samples (Fig. 3.1A), suggesting an important role for this 
cytokine. As reported previously, IL-6 is pivotal in several cancers (93), including Kaposi 
sarcoma, multiple myeloma, and Hodgkin lymphoma. It is correlated with a poor prognosis 
as it directly enhances proliferation of tumor cells, which is consistent with moderate 
stimulatory effect of IL-6 on the proliferation of human oligodendroglioma cells (Fig. 
3.6A). Therefore, we postulate that OSM and IL-6 stimulate the proliferation of 
oligodendroglioma cells, and promote growth of tumors in vivo.   
IL-6 and OSM signal via receptor complexes that cause the recruitment and 
subsequent phosphorylation of STAT3, which leads to its dimerization, nuclear 
translocation, and ultimately the activation of target genes (128). Furthermore, STAT3 is 
constitutively activated in a variety of cancers, including glioblastoma, leukemia, 
lymphoma, breast, lung, and prostate (93). Activated STAT3 is present in both tumor cells 
and immune cells, and it enhances tumor cell proliferation, inhibits the expression of 
mediators necessary for anti-tumor immunity, and thus leads to tumor-induced immuno-
suppression (212). Similarly, we found that STAT3 is constitutively phosphorylated in OD 
samples (Fig. 3.3A). As previously reported in other cancers (93), STAT3 regulates genes 
promoting proliferation and survival, such as Myc, cyclin D, BCL-XL, survivin, and MCL-
108 
1. It also promotes angiogenesis and invasiveness by increasing the expression of VEGF, 
HIF-1, and MMPs. In addition, immunosuppressive effects of STAT3, which lead to 
diminished cytotoxicity of neutrophils and NK cells, reduced antigen presentation by 
APCs, decreased T-cell activation, and tumor infiltration, is critical for tumor progression. 
Thus, similar to other cancers, STAT3 likely promotes oligodendroglioma growth, inhibits 
apoptosis, and suppresses the anti-tumor immune response.  
In GBMs, persistent activation of STAT3 is mediated by autocrine IL-6 signaling, 
or by activated EGFR (166), which is often mutated or amplified. In contrast, EGFR is not 
commonly affected in oligodendrogliomas. Therefore, activation of STAT3 in 
oligodendroglioma may result from enhanced OSM, and/or IL-6 signaling in these tumors. 
Hence, STAT3 activated by OSM and IL-6 is likely crucial for the progression of OD 
tumors. 
Moreover, OD samples contain moderate amounts of IL-1. As a matter of fact, IL-1 
is the major neuro-inflammatory cytokine during inflammation and is abundantly 
produced, thus stimulating both the growth and invasiveness of malignant cells. In 
addition, polymorphisms in the promoters of genes encoding IL-1β and IL-1RA have been 
associated with an increased risk of cancer (174). Despite its well established role in other 
tumors (6), IL-1 is elevated only in half of the OD samples (Fig. 3.1A). Although it does 
not affect the proliferation of oligodendroglioma cells (Fig. 3.6A), it stimulates its own 
production as well as other inflammatory cytokines (Fig. 3.2), and activates NF-κB in 
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these cells. Both, IL-1 and TNFα activate the classical IKK/NF-κB pathway in many cell 
types, which promotes cell proliferation and survival (76). However, the phosphorylation 
status of RelA was not affected in OD samples (Fig. 3.5E) despite an efficient IL-induced 
phosphorylation of RelA (Fig. 3.5F), and activation of NF-κB-responsive genes (Fig. 
3.2A-B) in oligodendroglioma and shwannoma cells in vitro. This apparent discrepancy 
may be explained by limitations of the in vitro model, which mimics an acute 
inflammatory response of the tumor cells, while a chronic inflammatory state develops in 
vivo. Furthermore, neither IL-1 nor TNFα affected the proliferation of HOG cells, and 
TNFα caused their apoptosis as indicated by the PARP-1 cleavage (Fig. 3.6). We conclude 
that the oligodendroglioma tumors depend on OSM/IL-6-activated STAT3 pathway, while 
they are independent of IL-1/TNFα-induced NF-κB signaling.  
During a resolution phase of inflammation (191), homeostasis is restored via the 
secretion of acute phase proteins, such as ACT (114). Therefore, ACT is a good marker of 
inflammation (1), which is activated by many cytokines, including IL-1 and OSM in 
astrocytes (116, 117). Interestingly, ACT expression was noticeably higher in most of the 
OD samples (Fig. 3.3A), which is most likely caused by the activated STAT3, as the ACT 
gene is STAT3-dependent (Fig. 3.4D). Although, the IKK/NF-κB pathway was not 
activated in OD samples, ACT was upregulated by IL-1-induced NF-κB in 
oligodendroglioma and shwannoma cells (Fig. 3.4). Thus ACT regulation in 
oligodendroglioma and shwannoma cells parallels that in human astrocytes and 
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glioblastoma cells. It is noteworthy that the basal ACT level is extremely low in 
oligodendroglioma and shwannoma cells (Fig. 3.3B); however, it is drastically increased 
by either IL-1 or OSM (Fig. 3.3C). Therefore, astrocytes and glioma cells are not the sole 
source of ACT in the nervous system, as ACT is also produced by oligodendroglioma and 
schwannoma cells. In support of our findings, ACT has been detected in 
oligodendrogliomas and schwannomas by immunocytochemistry (120, 154). Collectively, 
ACT is an important component of the inflammatory network associated with the tumor 
microenvironment, and its role may be to protect from apoptosis and enable spreading of 
the tumor cells, all of which should be addressed in brain tumors. 
In summary, we propose a model of interdependent cytokine communication between the 
cells within the oligodendroglioma tumor milieu (Fig. 3.8). The pro-inflammatory 
cytokines, such as IL-1, IL-6, OSM, MCP-1 as well as markers of ongoing inflammation, 
such as ACT and COX-2, are expressed in these tumors. MCP1, secreted by the tumor 
cells, recruits and activates macrophages and microglia to the tumor site. Subsequently, IL-
1 induces the expression of COX-2 in endothelial and microglial cells, which leads to the 
production of PGE2 in these cells. PGE2 induces the expression of OSM in microglia and 
macrophages, which in turn activates STAT3 in the oligodendroglioma cells, and thus 
stimulates their proliferation. Simultaneously, STAT3 is activated in other immune cells, 
and leads to the suppression of the anti-tumor response. These data strengthen the position 





Fig. 3.8. Proposed model of inflammation within an oligodendroglioma tumor. Pro-
inflammatory cytokines, such as IL-1, IL-6, and MCP-1 as well as markers of 
inflammation, including ACT and COX-2, are present within the oligodendroglioma tumor 
milieu. Chemokines secreted by the tumor cells recruit immune cells, including 
macrophages, lymphocytes, and microglia, which are subsequently activated by tumor-
derived cytokines. IL-1 induces the expression of COX-2 in endothelial and microglial 
cells, leading to the production of PGE2 in these cells. PGE2 acts on microglia and 
macrophages to induce the expression of OSM, which in turn activates STAT3 in the 


















The mechanisms controlling gene expression during the differentiation of 
astrocytes are poorly understood, even though astrocytes are critical for the development 
and progression of many pathological states of the brain, including neuroinflammation 
associated with neurodegenerative diseases. The published data suggest that several 
signaling pathways are critical for astrocyte differentiation, including the JAK-STAT, 
BMP-2/Smads, and Notch signaling. More recently, emerging evidence suggested that a 
family of Nuclear Factor-1 (NFI-A, NFI-B, NFI-C, NFI-X) regulates the development of 
vertebral neocortex, with NFI-A and NFI-B specifically controlling the onset of 
gliogenesis. Here, we developed and characterized an in vitro model of differentiation of 
stem cells towards neural progenitors and subsequently astrocytes. The transition from 
stem cells to progenitors was accompanied by a proper change in the expression profile of 
differentiation markers, including Sox-2, Musashi-1, and Oct4. Furthermore, the generated 
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astrocytes were characterized by proper morphology, increased glutamate uptake, and 
expression of marker genes. We used this in vitro differentiation model to study NFI role 
in stem cell maturation. Interestingly, embryonic stem cells expressed only background 
levels of NFIs, while differentiation to neural progenitors was accompanied by 
upregulation of NFI-A expression. More importantly, NFI-X expression was induced 
during the final stages of differentiation towards astrocytes. In addition, NFI-C and NFI-X, 
but not NFI-A or NFI-B were required for the expression of GFAP and SPARCL1, which 
are the markers of terminally differentiated astrocytes. We conclude that an expression 
program of NFIs is executed during the differentiation of astrocytes, with NFI-C and NFI-
X controlling expression of terminal astrocytic markers.  
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2. INTRODUCTION 
Astrocytes are critical for the development of many pathological states in the brain (19, 
123, 147, 208), including neuroinflammation associated with neurodegenerative diseases 
and progression of brain tumors.  Furthermore, a loss of astrocyte-specific markers is the 
hallmark of gliomas (71), suggesting that they represent cells that have escaped 
differentiation at different stages.  Despite the crucial role of astrocytes in the brain, the 
mechanisms controlling astrocyte-specific gene expression and differentiation are only 
partially understood.   
The data accumulated over the years suggest that several signaling pathways are 
indispensable for astrocyte differentiation and expression of astrocyte-specific markers.  
These include the JAK-STAT and the BMP-2-Smads pathways, the activation of Notch 
signaling, and the expression of Nuclear Factor-1 (NFI) family of transcription factors (82, 
143, 179).  During vertebrate embryonic development, gliogenesis follows neurogenesis, 
and is likely triggered by the activation of the JAK-STAT signaling pathway in neural 
precursors by neuron-derived cardiotrophin-1 (12).  Specifically, STAT3 is believed to be 
critical for the generation of astrocytes (87), and its effect is synergistic with bone 
morphogenic protein-2 (BMP-2), which activates Smad1 (158).  Smad1 then forms a 
complex with STAT3, which is bridged by the coactivator p300, and this results in 
synergistic induction of astrogliogenesis (152).  In addition to JAK-STAT and BMP-
Smad1 pathways, Notch signaling also affects gliogenesis by activating the transcriptional 
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activity of RBP-Jκ (77).  RBP-Jκ can promote gliogenesis only when the JAK-STAT 
pathway is active (68). When the JAK-STAT pathway is not activated, RBP-Jκ binds to a 
repressive cofactor protein, NCoR, which represses gliogenic genes (90).  Recently, it 
became apparent that the NFI family of transcription factors also regulates gliogenesis; 
however, their role in this process, and the subsequent expression of astrocyte-specific 
genes, is not known. 
The phylogenetically conserved NFI family of proteins regulates the expression of 
various cellular and viral proteins, as well as viral DNA replication (79).  These 
transcription factors are encoded by four, highly conserved genes: Nfia, Nfib, Nfic, and 
Nfix (165).  In vertebrates, products of these genes (NFI-A, NFI-B, NFI-C, and NFI-X) 
share a conserved N-terminal sequence, containing both DNA binding and dimerization 
domains (157).  However, significant variations occur within the C-terminal 
transactivation domains of the NFI proteins (79).  In addition, transcripts of all four genes 
can be alternatively spliced, yielding as many as nine different proteins from a single gene 
(80). 
In mammals, the NFI genes are expressed in complex, overlapping patterns during 
embryogenesis (34), with particularly high levels of expression of NFI-A, NFI-B, and NFI-
X in the developing neocortex (163).  Binding sites for NFI proteins are present in genes 
expressed in multiple tissues, but also in genes expressed solely in the brain, muscle, liver, 
or specific cell types (79).  More recently, Nfia, Nfib, Nfic, and Nfix genes have been 
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successfully disrupted in mice.  Disruption of either the Nfia (47, 184) or Nfib (189) gene 
causes late gestation neuroanatomical defects, including agenesis of the corpus callosum, 
size reduction in other forebrain commissures, loss of specific midline glial populations, 
and a 5-10 fold decrease in the levels of glial fibrillary acidic protein (GFAP), a specific 
marker of astrocytes.  In addition, Nfib-deficient mice show aberrant hippocampus and 
pons formation, and defects in lung development.  In contrast, disruption of the Nfic gene 
results in early postnatal defects in tooth formation, including the loss of molar roots and 
aberrant incisor development (188).  Loss of the Nfix gene is postnatally lethal, and leads 
to hydrocephalus and agenesis of the corpus callosum.  Furthermore, NFI-X-deficient mice 
develop a deformation of the spine with kyphosis, due to a delay in ossification of 
vertebral bodies and a progressive degeneration of intervertebral disks (58).  Collectively, 
these data suggest that NFI-A, NFI-B, and NFI-X isoforms play an important role in brain 
development. In fact, it has been recently demonstrated that both NFI-A and NFI-B affect 
gliogenesis in the chick embryo (53). Moreover, NFI-A is also necessary for the 
maintenance of neural precursors. Interestingly, NFI-A expression precedes NFI-B 
expression in the developing chick embryo, suggesting a sequential expression of NFI 
isoforms, with NFI-A expressed in early stages, followed by NFI-B, and then NFI-C and 
NFI-X. Altogether, these data indicate that NFI-A and NFI-B may be critical in the initial 
stages of gliogenesis, while the functions of NFI-C and NFI-X are not known.  Therefore, 
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we initiated this study to clarify the role of the NFI isoforms in astrogliogenesis using an in 
vitro differentiation model.  
Here, we find that NFI-C and NFI-X are expressed later during the astrocyte 
differentiation process, and are required for the expression of astrocyte markers, including 
GFAP and SPARCL1.  We also demonstrate that human embryonic stem cells and derived 
neural progenitors are an excellent in vitro model to study the mechanisms of astrocyte 
differentiation. 
119 
4.3. MATERIALS AMD METHODS 
4.3.1. Human embryonic stem cell culture. Human BG01VV embryonic stem cell line 
was cultured on mitomycin C-inactivated mouse embryonic fibroblasts (MEF) layer. Cells 
were cultured in DMEM/F12 medium, supplemented with 20% knockout serum 
replacement (KSR) (Gibco, Grand Island, NY), 1 mM L-glutamine, 0.1 mM nonessential 
amino acids, 50 U/ml penicilin, 50 µg/ml streptomycin, 4 ng/ml basic fibroblast growth 
factor (bFGF) (PeproTech, Rocky Hill, NJ), and 0.1 mM β-mercaptoethanol. Cells were 
propagated in 4 day cycles, and enzymatically passaged with collagenase and trypsin.   
 
4.3.2. Human primary astrocytes culture. Human cortical astrocyte cultures were 
established using dissociated human cerebral tissue as previously described (117). Cortical 
tissue was provided by Advanced Bioscience Resources (Alameda, CA), and the protocol 
for obtaining postmortem fetal neural tissue complied with the federal guidelines for fetal 
research and with the Uniformed Anatomical Gift Act. Cells were cultured in Dulbecco's 
modified Eagle's medium supplemented with 10% fetal calf serum, penicillin and 
streptomycin, sodium pyruvate, and non-essential amino acids. 
 
4.3.3. Generation of neural progenitors. In order to generate neural progenitors, 
BG01VV cells were allowed to proliferate for 7 days as described previously (183). 
Briefly, cells were grown in DMEM/F12, supplemented with 15% defined FBS (Hyclone, 
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Logan, UT) and 5% KSR, 2 mM L-glutamine, 0.1 mM nonessential amino acids, 50 U/ml 
penicilin, 50 µg/ml streptomycin, 4 ng/ml bFGF, and 10 ng/ml leukemia inhibitory factor 
(LIF) (Chemicon, Temecula, CA). Subsequently, cells were grown for an additional 7 days 
in differentiation medium composed of DMEM/F12, N2 supplement (Gibco, Grand Island, 
NY), 2 mM L-glutamine, 50 U/ml penicilin, 50 µg/ml streptomycin, and 4 ng/ml bFGF. 
Following this stage, the MEF layer was removed and cells were dissociated by DPBS 
without calcium and magnesium, followed by collagenase and trypsin incubation. Cells 
were then plated on laminin and poly-L-ornithin coated dishes, propagated in NB27 
medium consisting of neurobasal medium, B27 supplement (both from Gibco, Grand 
Island, NY), 2 mM L-glutamine, 50 U/ml penicilin, 50 µg/ml streptomycin, 20 ng/ml 
bFGF, and 10 ng/ml LIF. Cells were maintained by passaging using trypsin.  
 
4.3.4. Differentiation into astrocytes and oligodendrocytes. To generate astrocytes, 
neural progenitors were cultured on laminin and poly-L-ornithin coated dishes in DMEM, 
supplemented with 10% FBS, 2 mM L-glutamine, 50 U/ml penicilin, 50 µg/ml 
streptomycin, and nonessential amino acids for 21 days. To generate oligodendrocytes, 
neural progenitors were grown on laminin and poly-L-ornithin coated dishes in NB27 
medium for 14 days, which was followed by culture in the same medium with the addition 
of 5 ng/ml PDGF (Peprotech, Rocky Hill, NJ) and 50 µM 3,3’,5-Triiodo-L-thyronine 
(Sigma, Saint Louis, MO) for 6 days.  
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4.3.5. Down-regulation of target genes. Expression of NFI-A, -B, -C, -X genes was 
down-regulated using SmartPool siRNAs from Dharmacon (Dharmacon, Int., Lafayette, 
CO). siRNAs were transfected into neural progenitor cells on day 15 of differentiation, by 
using Dharmafect 1 reagent (Dharmacon, Inc., Lafayette, CO), according to the 
manufacturer’s instructions. Subsequently, efficiency of target gene downregulation was 
assayed by quantitative PCR 6 days post-transfection. 
 
4.3.6. RNA isolation and Quantitative PCR. Total cellular RNA was prepared by Trizol 
(Invitrogen, Carlsbad, CA), following the manufacturer’s protocol. Subsequently, one µg 
of total RNA was reverse-transcribed using the High Capacity cDNA Archive kit (Applied 
Biosystems, Foster City, CA).  GFAP, CD44, GLAST, SPARCL, S100B, BFABP, nestin, 
vimentin, NFI-A, -B, -C, -X, and GAPDH mRNA levels were measured using pre-mixed 
primer-probe sets, and TaqMan Universal PCR Master Mix according to the supplier’s 
instructions (Applied Biosystems, Foster City, CA). The cDNAs were diluted 10-fold (for 
the target genes) or 100-fold (for GAPDH), and amplified using the ABI 7900HT cycler. 
Gene expression levels were normalized to GAPDH mRNA levels and presented as fold 
induction with mean values +/- standard deviation. Statistical analysis was performed by 
one-way analysis of variance. Differences were considered statistically significant when p-
values were <0.05.  
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4.3.7. Immunocytochemistry. For immunocytochemical staining, neural progenitor cells 
were differentiated in 4-well chamber slides (Nunc, Rochester, NY). After 21 days in 
culture, cells were washed with PBS, fixed with 3% formaldehyde for 15 min at room 
temperature, and washed once more with PBS. Cells were then permeabilized in 0.3% 
TritonX-100 in PBS for 10 min at 20°C, except when later stained for O1 surface marker. 
Slides were washed twice in PBS and blocked in 10% milk/0.1% goat serum in PBS for 3 
hours. Subsequently, cells were incubated with primary antibodies against O1 (1:500), 
GFAP (1:600), βIII-tubulin (1:1000) or isotype control nonspecific sera (Chemicon, 
Temecula, CA) overnight at 4°C in the blocking solution. This was followed by 5 times 
washing with PBS and a 3 hour incubation with the corresponding fluorescent secondary 
antibodies in the blocking solution. After washing 5 times with PBS, cells were refixed 
with 3% parafolmadehyde for 15 minutes at 20°C, washed with PBS and dried. Coverslips 
were mounted over the chamber slides using 1.5µg/ml Vectashield Mounting Media with 
DAPI. Images were captured on a confocal LSM 510 Meta Zeiss microscope with a 100x 
objective using the appropriate laser excitation. 
 
4.3.8. Western Blotting. Cells were lysed in 10 mM Tris pH 7.4, 150 mM sodium 
chloride, 1 mM EDTA, 0.5% NP-40, 1% Triton X-100, 1 mM sodium orthovanadate, 0.2 
mM PMSF, and protease inhibitor cocktail (Roche, Mannheim, Germany).  Samples were 
resolved using SDS-PAGE, and electroblotted onto nitrocellulose membranes (Schleicher 
& Schuell, Keene, NH). Polyclonal anti-Oct-4 (1:1000), anti-Sox2 (1:1000), and anti-
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Musashi-1 (1:500) antibodies were purchased from Chemicon (Chemicon, Temecula, CA). 
Anti-β-tubulin polyclonal antibodies were from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA).  Antigen-antibody complexes were visualized by enhanced chemiluminescence 
using Immobilon Western according to the manufacturer’s instructions (Millipore, MA). 
 
4.3.9. Glutamate Uptake Assay. The uptake of [3H]-glutamate (Amersham, UK) was 
determined as previously described (*). Briefly, cells were grown in a 12-well plate, and 
the medium was replaced by fresh DMEM, supplemented with 10% FBS, non-essential 
aminoacids, and penicillin/streptomycin, 50 µM glutamate (Sigma, St. Louis, MO), and 
18.5 kBq (9.25 pmol) [3H]-glutamate. Cells were incubated for 15 minutes at 37°C, and 
then washed three times with ice-cold PBS containing 5 mM glutamate. After cell lysis in 
0.5 ml of 10 mM NaOH with 0.1% Triton X-100, 300 µl of the lysate aliquotes were 
assayed for 3H radioactivity by liquid scintillation counting, and 100 µl were used for 
measuring protein concentration by the BCA method (Sigma, St. Louis, MO). Statistical 
analysis was performed by one-way analysis of variance. Differences were considered 
statistically significant when p-values were <0.05.  
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4.4. RESULTS 
4.4.1. Generation of neural progenitors 
Thus far, human fetal brain neural progenitor cells have been differentiated in vitro into 
cells expressing markers for either neurons or astrocytes, with 70% and 100% efficiency, 
respectively (164, 183). However, the supply of human fetal tissue is limited due to ethical 
issues. Therefore, the use of commercially available human embryonic stem cells (153), 
including the BG01V cell line used in these studies offer a potential alternative. These and 
other embryonic stem cell lines have been successfully differentiated into neural 
progenitors, and further into cells expressing markers of astrocytes, neurons, and 
oligodendrocytes. We used these cells as an in vitro model to study the mechanisms of 
astrocyte differentiation. First, we successfully differentiated BG01V cells into neural 
progenitors as described earlier (*). These progenitors are characterized by rosette-forming 
structures, and are capable of growing in culture without the mouse feeder layer (Fig. 
4.1A). To further characterize the cultures, we have analyzed the expression of pluripotent 
stem cell (Oct-4) (155) and neural progenitor (Musashi-1) (107) markers by Western 
blotting (Fig. 4.1B.). The expression of Musashi-1 was much higher in neural progenitor 
cells than in the stem cells. In addition, the transcription factor Oct-4 was no longer 
expressed in the NP cells. Furthermore, the expression of Sox2 was abundant in both cell 
types (10). Collectively, these data indicate that BG01V cells were successfully 





Fig. 4.1. BG01V embryonic stem cells differentiate into neural progenitors. (A) 
Contrast phase microscopic images of embryonic stem cells grown on a MEF feeder layer 
(left), and generated neural progenitors grown on laminin (right). Arrows point to stem cell 
colonies. (B) Cells were trypsinized, washed, lysed, and the expression of cell-specific 
markers was analyzed by western blotting as described in the M&M section. β-tubulin was 
used as a loading control. 
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4.4.2. Neural progenitors as a model for astrocyte differentiation. 
 Due to the limitations of in vivo methods to study specific mechanisms of cellular 
differentiation, we aimed at developing an in vitro differentiation model consisting of stem 
cells and neural progenitors.  First, we assessed if the BG01V-derived neural progenitors 
can further differentiate into astrocytes by evaluating the expression of multiple markers in 
stem and progenitor cells, and then compared them to primary human astrocytes (Fig. 
4.2A).  This analysis included genes expressed in astrocytes, such as glial fibrillary acidic 
protein (GFAP) (62), glutamate transporter (GLAST) (182), CD44 antigen (131), calcium-
binding protein S100β (219), and secreted protein acidic and rich in cystein-like protein 1 
(SPARCL1/hevin) (141).  The expression of these markers was extremely low in BG01V 
and neural progenitor cells, however it was drastically high in primary human astrocytes.  
In addition, neural progenitor cells expressed significant levels of S100β, GLAST, and 
SPARCL1 mRNA (Fig. 4.2A), which is in accordance with previously published data that 
showed the presence of these markers in other cells in the brain. Subsequently, we 
analyzed the expression of the brain fatty acid binding protein (B-FABP) (121), which is 
abundantly expressed in radial glia and immature astrocytes in vivo. Indeed, BFABP was 
expressed at relatively low levels in stem and progenitor cells, whereas its expression was 





Fig. 4.2. Characterization of gene expression patterns in generated neural 
progenitors. RNA was prepared from BG01V cells (ESC), neural progenitors (NP), and 
human primary astrocytes (Astr), which serve as a positive control. Subsequently, 
expression of glial marker mRNAs (A), and mRNAs for the different NFI isoforms (B) 
was measured by qPCR (Taqman). Data were normalized to GAPDH mRNA levels, and 
are represented as a relative fold induction in reference to embryonic stem cells. Assays 
were performed in triplicates and the data represent the mean +/- standard deviation (error 
bars) with p<0.01.  
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Vimentin and nestin are the early intermediate filament proteins present in 
progenitor and early precursor cells, and are later replaced by GFAP in mature astrocytes 
(61, 161). Thus, we analyzed the expression of these markers in BG01V and neural 
progenitor cells.  We found that neural progenitors express higher levels of nestin and 
vimentin than stem cells (Fig. 4.2A); however, these markers are also expressed at high 
levels in primary human astrocytes, suggesting that these cells are immature. In fact, 
primary astrocytes in culture express all of the intermediate filament proteins (181), 
including nestin, vimentin, and GFAP, a situation, which is similar to that observed in 
reactive astrocytes in vivo. In addition, human primary astrocytes were isolated from 
fetuses at the 18th week of gestation, which corresponds to the onset stage of gliogenesis; 
thus, they are likely heterogenous and comprise cells at different stages of differentiation, 
which cannot be separated by commonly used isolation methods. 
Since the BG01V-derived neural progenitor cells express very low levels of GFAP, 
BFABP, and CD44, while they express higher levels of S100β, GLAST, vimentin, and 
nestin, they represent the undifferentiated progenitor cells in the brain which have the 
potential to differentiate into astrocytes, neurons, or oligodendrocytes. Therefore, we 
conclude that these BG01V-derived neural progenitors are a good starting point for 





Fig. 4.3. Differentiation of neural progenitors into astrocytes. Neural progenitors (NP) 
were subjected to the astrocyte differentiation protocol as described in the M&M section. 
(A) Contrast phase microscopic images of neural progenitors (left), generated astrocytes 
(center), and human primary astrocytes (right). (B) Immunocytochemical staining of 
differentiated astrocytes with anti-GFAP, secondary antibodies (NS), anti-O1, anti-
βIIItubulin, and DAPI (blue) was performed as described in the M&M section. (C) 
Glutamate uptake was assayed in cultured neural progenitors (NP), generated astrocytes 
(Diff. Astr), and primary human astrocytes (Astr) as described in the M&M section. 
Protein concentration was measured by the BCA assay. Data are expressed in picomoles of 
glutamate per mg of cellular protein. Experiment was performed in triplicates, and error 







4.4.3. Expression of NFI isoforms in stem cells and neural progenitors. 
 Expression of NFI isoforms is developmentally regulated in the CNS, with NFI-A, 
-B and -X knockout mice presenting severe neuroanatomical defects (47, 58, 189). 
However, the specific functions of each NFI isoform in the brain remain unknown. 
Furthermore, it is not clear which isoforms are crucial for proper differentiation of 
particular brain cell types, including astrocytes. In order to determine if BG01V stem cells 
and progenitors can be used to study the role of NFI isoforms in the process of 
differentiation, we analyzed the pattern of NFI expression in stem cells and neural 
progenitors, and compared it to primary human astrocytes (Fig. 4.2B). Indeed, the 
embryonic stem cells express only minute amounts of mRNAs for all NFI isoforms when 
compared to primary astrocytes, in which the NFI expression is tens- or hundreds- fold 
higher. More importantly, NFI-A expression was dramatically increased in neural 
progenitor cells, indicating that these cells underwent the expected differentiation process. 
In addition, there was a several fold increase in the expression of NFI-C and NFI-B in the 
neural progenitor cells, suggesting that these isoforms may be the next NFIs activated 
during differentiation. We conclude that the in vitro differentiation model may be used to 
study the terminal differentiation of neural progenitor cells into astrocytes, neurons, and 




4.4.4. Generation of astrocytes. 
 Recently, both rat and human neural progenitors were differentiated towards 
astrocytes in vitro (153, 164).  We have followed the protocols with some modifications 
(183), and generated cells that were subsequently analyzed for the expression of specific 
markers. Morphologically these cells resembled primary astrocytes, as they showed a 
spread-out flat body and uniform distribution with characteristic projections, in contrast to 
the more compact and round neural progenitor cells forming the rosettes (Fig. 4.3A). In 
addition, all of the cells were GFAP-positive, but O1- and βΙII-tubulin-negative, which are 
the astrocyte, oligodendrocyte and neuronal markers, respectively (Fig. 4.3B). In order to 
further confirm the identity of the generated cells, we performed a functional glutamate 
uptake assay. Indeed, primary human astrocytes demonstrated a 2-fold increase in 
glutamate uptake when compared to the original neural progenitor cells. Furthermore, 
astrocytes generated from the neural progenitor cells had a significant increase of 40% 
(Fig. 4.3C), a good indication of their differentiation. It is noteworthy that many cells 
underwent apoptosis or became senescent as part of the differentiation process, hence the 
overall survival was low (10-20%), and the differentiated astrocytes lost their proliferative 
potential. Furthermore, BFABP, GFAP, SPARCL1, and CD44 mRNA levels were 
significantly increased in the differentiated astrocytes in comparison to neural progenitor 
cells (Fig. 4.4A). As expected, nestin expression was decreased (4-fold), while vimentin 




Fig. 4.4. Characterization of gene expression patterns in differentiated astrocytes. 
Neural progenitors were subjected to the astrocyte differentiation protocol as described in 
the M&M section. On day 21, the expression of glial markers (A) and NFI isoforms (B) 
was measured by qPCR (Taqman) in the differentiated astrocytes (Diff. Astr), and 
compared to BG01V embryonic stem cells (ESC) and neural progenitors (NP). Data were 
normalized to GAPDH mRNA, and are represented as a relative fold induction in reference 
to the ESC. Assays were performed in triplicates, and the results represent the mean +/-
standard deviation (error bars) with p<0.05.  
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differentiation. Interestingly, the generated cells expressed S100β and GLAST at similar to 
neural progenitors levels. Although S100β is produced by astrocytes, it is present at low 
levels in many neural cell types in the brain. It is also an indicator of astrocytic damage and 
disfunction, since it is abundantly expressed by activated astrocytes (219). Similarly, 
GLAST is co-expressed with NFI-A already in the progenitors destined to become glia in 
vivo (53).  As a negative control, we analyzed the expression of myelin basic protein 
(MBP), a marker of differentiated oligodendrocytes (214), during astrocyte differentiation, 
and we did not detect any MBP expression in this process (data not shown). In addition, 
we have quantified the expression of Olig2, the oligodendrocyte-lineage transcription 
factor (173), and we found that Olig2 was already present in the NP cells, and it decreased 
20-fold in the differentiated astrocytes (data not shown). Collectively, these results indicate 
that neural progenitors underwent proper differentiation towards astrocytes, but not 
neurons or oligodendrocytes, as indicated by the expression of appropriate glial markers.  
 
4.4.5. NFI expression is sequential during astrocyte differentiation. 
Since the neural progenitors express significant amounts of NFI-A, very low levels of 
NFI-B and NFI-C but not NFI-X, we investigated whether the expression of NFI isoforms 
is further induced during the process of differentiation (Fig. 4.4B). Indeed NFI-X 





Fig. 4.5. NFI-C and NFI-X regulate the expression of GFAP and SPARCL1 during 
astrocyte differentiation. Neural progenitors were subjected to the astrocyte 
differentiation protocol for 21 days. On day 15 of the differentiation process, cells were 
transfected with non-targeting control siRNA, siRNA targeting NFI-C and NFI-X ((C+X) 
siRNA), or siRNA targeting all NFI isoforms (panNFI siRNA). RNA was then isolated on 
day 21, and the expression of (A) glial markers and (B) NFI isoforms were analyzed in 
triplicates. Data were normalized to GAPDH mRNA, and are presented as a fold induction 
in reference to untreated, differentiated astrocytes. Satistical significance was estimated by 
values of p<0.0001 for GFAP, SPARCL1, NFI-C, and NFI-X genes and p<0.05 for 
BFABP, S100B, NFI-A, and NFI-B genes. 
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In contrast, the expression of NFI-A and NFI-B increased 2-fold, while the expression of 
NFI-C was unchanged. These data suggest that NFI-A and NFI-B may be crucial at the 
initial stages of astrocyte differentiation and maintenance of progenitor cells. Later, NFI-X, 
and possibly NFI-C, may regulate gene expression during the final stages of astrocyte 
differentiation. 
 
4.4.6. NFI-C and NFI-X control astrocyte-specific gene expression. 
To further study the role of NFI in the expression of astrocyte-specific markers, we 
knocked-down the expression of specific NFI isoforms during the differentiation process. 
Since simultaneous down-regulation of NFI-C and NFI-X isoforms is required to diminish 
GFAP expression in primary human astrocytes (data not shown), we applied siRNAs 
targeting both NFI-C and NFI-X on day 15 of astrocyte differentiation. For comparison, 
we used combined Smart Pool siRNAs for all NFI isoforms (PanNFI siRNA), and a non-
targeting control siRNA. Subsequent marker gene expression analysis on day 21 revealed 
that the knockdown of NFI-C and NFI-X drastically decreased the expression of the GFAP 
and SPARCL1 genes by 80% and 50%, respectively (Fig. 4.5A). In contrast, there was no 
effect on GLAST, CD44, or nestin and a moderate effect (25%) was observed on S100β 
and BFABP mRNA levels. Since simultaneous knockdown of all NFI isoforms did not 
have any additional effect on the expression of analyzed markers, we conclude that NFI-C 
and NFI-X are the major NFIs required for the expression of GFAP and SPARCL1. The 
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efficiency of the target NFI down-regulation was 60-90%. We did not observe any non-
specific effects of either the specific siRNAs or the control siRNA (Fig. 4.5B).  In 
summary, both NFI-C and NFI-X are required for the expression of the GFAP and 




Currently, there is ongoing research on human stem and progenitor cells aimed at 
using the modified cells as replacements for cells lost during disease (PD, MS, Cerebral 
Palsy) (72) or as tools to deliver drugs to the target sites of disease by ‘homing in’ (GBM) 
(148). Particularly, understanding the processes controlling glial differentiation may have 
critical consequences in future therapies of gliomas and neurodegenerative disorders. Thus 
far, differentiation and functional studies have been done using rodent neural progenitors 
(164). Although research on animal cellular differentiation provides the basic knowledge 
of the processes, it cannot be directly extrapolated to the human system and used to 
analyze the mechanisms regulating genes, which may be different between humans and 
rodents. In this regard, most of the neurodegenerative disorders are typically human, as 
rodents do not develop AD, MS, nor PD diseases. Recently, human neural progenitors 
have been isolated from epileptic patients or human fetal tissue, and directed to develop 
into different brain cell types (125, 171). However, these types of studies are always 
controversial and thus, there is a need for functional in vitro models recapitulating 
molecular mechanisms of cellular differentiation in the brain. Moreover, stem cell 
pluripotency must be handled properly so that it leads to the generation of a desired and 
functional cell type of the CNS. Therefore, extensive studies in this area, including the 
mechanisms regulating the differentiation of neurons, astrocytes, and oligodendrocytes, are 
absolutely necessary.  
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Here, we have employed human BG01V stem cells to generate neural progenitors, 
which were further differentiated towards astrocytes. This in vitro astrocyte differentiation 
model allowed us to study the involvement of transcription factors and mechanisms of 
gene regulation. Moreover, it allowed us to monitor the gene expression in the course of 
the differentiation process, and analyze the effects of specific gene knock-down. Therefore, 
this is a very good in vitro model to study glial cell differentiation, which may contribute 
to the future stem cell-based therapies.  
The analysis of the marker gene expression patterns proved that stem cell-derived 
neural progenitors are excellent candidates for further differentiation into astrocytes (Fig. 
4.2A). These neural progenitor cells were successfully differentiated towards astrocytes, as 
characterized by astrocyte-like morphology and increased glutamate uptake (Fig. 4.3). 
Moreover, we also demonstrated dramatically increased expression of GFAP, SPARCL1, 
BFABP, and CD44 genes in the cells differentiated towards astrocytes (Fig. 4.4).  
GFAP is an intermediate filament that replaces vimentin and nestin during the 
differentiation of astrocytes in vivo. It is detected in the later stages of brain development, 
and its expression increases with time (62).  Although GFAP can also be present in 
embryonic stem cells, it is expressed by mature astrocytes at levels that are hundreds fold 
higher. Importantly, BG01V stem cells and neural progenitor cells express only minute 
amounts of GFAP. However, their in vitro differentiation resulted in approximately 100 
fold higher expression of GFAP. 
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Furthermore, SPARCL1 (or hevin), a matricellular protein widely expressed in the 
embryonic and neonatal brain and vasculature, is gradually expressed at higher levels 
during development (141). Therefore, its increased expression levels indicate the 
progression of differentiation. Accordingly, very low SPARCL1 levels were found in the 
embryonic stem cells (Fig. 4.2A), increased in the neural progenitor cells, and peak in 
astrocytes. 
On the other hand, CD44 is a receptor for hyaluronic acid expressed by astrocyte-
restricted precursors in the developing rodent spinal cord before the acquisition of GFAP 
immunoreactivity. Moreover, CD44 does not co-localize with neuronal or oligodendroglial 
markers (131). The increased expression of CD44 in the differentiated astrocytes versus 
the progenitor and stem cells indicates that these cells followed the astrocyte differentiation 
pathway in our in vitro differentiation model.  
In the developing brain, BFABP is abundantly expressed by radial glia, the early 
precursors of astrocytes (121). High levels of its expression in differentiated astrocytes 
(Fig. 4.4A) may indicate an immature differentiation state, which also coincides well with 
CD44 expression.  
Conversely, S100β belongs to a family of Ca2+-binding proteins, and is localized to 
many cell types, including astrocytes, oligodendrocytes, microglia, and some neuronal 
subpopulations (219). Its expression defines cells which lose neural stem cell potential; 
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therefore, its presence in the generated neural progenitors and astrocytes concurring with 
its absence in the stem cells is a good indicator of the correct gliogenic differentiation.  
One of the main functions of astrocytes in the brain is to maintain low levels of 
glutamate within the perisynaptic regions by means of glutamate transporters in order to 
protect the neurons against glutamate-mediated cytotoxicity (46). However, during the 
neurogenesis period in brain development, before astrocytes are generated during 
gliogenesis, this function is performed by the neural progenitors (137). Therefore, 
significant glutamate uptake in the neural progenitor cells, which is further increased in the 
differentiated astrocytes, supports proper differentiation of the neural progenitor cells in 
this in vitro system. These observations coincide with the fact that GLAST is widely 
expressed in cortical progenitors during early developmental stages, and also by mature 
astrocytes.   
Nuclear Factor I is a family of ubiquitous transcription factors that are expressed 
during the development of the CNS (79). The role of NFI in astrocyte development is 
suggested by the presence of functional NFI-binding sites within the GFAP promoter (75). 
Furthermore, NFI-A and NFI-B direct the onset of gliogenesis in the developing mouse 
and chick spinal cord, with NFI-A also required for the maintenance of neural progenitors, 
specification of oligodendrocyte fate, and the inhibition of neurogenesis (53). However, 
there are no reports on the role of NFI on the mechanisms involved in the human CNS 
development. Therefore, the in vitro model that we propose is an attractive alternative to 
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study the differentiation of astrocytes, which overcomes the limitations of the knock-out 
studies. 
Our previous study showed that down-regulation of NFI-X decreases the 
expression of GFAP in U373 glioma cells (75). However, simultaneous down-regulation of 
NFI-X and NFI-C is required to affect GFAP expression in primary human astrocytes (data 
not shown). Moreover, GFAP levels are normal in both NFI-X and NFI-C KO mice (58, 
188), suggesting that these two isoforms share a high sequence homology and likely 
substitute for each other. Since NFI-X KO mice have a high post-natal lethality rate, 
making a double knock-out is very difficult. Here, we analyzed the effect of specific 
knock-down of NFI isoforms in the in vitro differentiation model. Significantly, a knock-
down of NFI-C and NFI-X is sufficient to down-regulate the expression of GFAP and 
SPARCL1, which are marker genes of differentiated astrocytes. It is noteworthy that 
GFAP expression was completely lost, whereas the expression of SPARCL1 was 
downregulated by 50%. This may be due to the fact that SPARCL1 is already expressed in 
the neural progenitor cells, independently of NFI, and its expression is probably controlled 
by other mechanisms, which also function in astrocytes. Interestingly, other marker genes 
were not affected by the NFI knock-down, suggesting that GFAP and SPARCL1 may be 
specifically regulated by these two NFI isoforms. In accordance with the fact that there are 
NFI-responsive elements within the BFABP promoter (18), NFI knock-down (C+X or pan-
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NFI siRNAs) had a moderate, yet significant effect on the expression of BFABP by 
differentiated astrocytes. 
In addition, knockdown of NFI-A or NFI-B at day 15 of differentiation did not 
have any effect on any of the astrocyte markers analyzed. In fact, NFI-A is co-expressed 
with GLAST at the onset of gliogenesis in the mouse and chick spinal cord (53). The same 
co-expression was observed in our in vitro model (Fig. 4.2A), as there is significant 
expression of NFI-A in neural progenitors that coincides with the expression of GLAST in 
these cells. Intriguingly, we observed an interesting expression pattern of NFI isoforms 
during cellular differentiation. All NFIs are hardly detectable in the ESC, while NFI-A 
expression is high and NFI-B and NFI-C levels are slightly increased in neural progenitor 
cells. However, NFI-X is expressed at significant levels only in differentiated astrocytes, 
and not in the progenitors. These data suggest that the NFI expression cascade exists 
during the differentiation of astrocytes, with NFI-A followed by NFI-B, NFI-C, and NFI-
X, which is expressed at the end of the differentiation process. This is also observed in vivo 
where NFI-A is expressed first, followed by NFI-B and NFI-X (34). However, the 
expression of NFI-C is concurrent with NFI-B, but it is at very low levels.  
Collectively, our data suggest that the expression of distinct NFIs is temporally 
regulated during astrocyte differentiation, and they are responsible for the expression of 
marker genes during the progression of gliogenesis. NFIs most likely cooperate with the 
JAK-STAT, BMP, and Notch pathways to promote astrocyte differentiation, which may be 
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coordinated around the formation of the CBP/p300 complex. Our study adds to the 
research on mechanisms of gliogenesis, and partly elucidates the mysterious role of NFI in 
the process of astrogenesis.  
 








Neuroinflammation is a term often used to describe inflammatory reactions within 
the CNS that are associated with pathological conditions, such as MS, AD, PD, HAD, 
schizophrenia, depression, epilepsy, trauma, and brain tumors (134). The 
neuroinflammatory reactions are driven by reactive microglia and astrocytes (147) (156), 
as well as infiltrating immune cells due to a disrupted brain blood barrier.  As a 
consequence, these cells secrete a plethora of inflammatory mediators, and express genes 
involved in cell proliferation, migration, and clearance of the pathogen and cellular debris 
that emerged locally. IL-1 is the major neuroinflammatory cytokine produced by both 
microglia and astrocytes in response to pathological conditions, and it is responsible for 
most of the subsequent cellular reactions (145). It induces the expression of other 
cytokines, chemokines, COX-2, iNOS, a series of adhesive proteins, and MMPs thus 
allowing extensive cell migration (103). Simultaneously, it induces the production of 
corresponding protease inhibitors, including TIMP-1 (192), to maintain the proteolytic 
balance in the ECM. Since the versatility of IL-1 actions in the brain is not fully 
understood, we investigated the mechanism by which IL-1 induces TIMP-1 expression in 
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primary human astrocytes (Chapter 2). We found that two signaling pathways, namely 
the IKK/NF-κB and p38/ATF-2, need to be activated simultaneously by IL-1 in order to 
induce the expression of TIMP-1 in primary human astrocytes. This mechanism is very 
similar to the one described in rheumatoid arthritis, where the chronic inflammation 
results in IL-1-mediated activation of NF-κB and p38, which regulate the expression of 
MMP-1 and MMP-3 in synovial fibroblasts (91). The mechanisms regulating MMPs 
expression often parallel that of their inhibitors in response to pro-inflammatory 
conditions, which is necessary to maintain the proteolytic balance. In contrast, IL-1 does 
not upregulate TIMP-1 in human glioblastoma cells due to the inactivation of either one 
of the branches of the IL-1-induced signaling. It is noteworthy that glioblastoma 
deregulate gene expression to shift the proteolytic equilibrium towards their favor, and 
promote cell invasion. TIMP-1 functions as a proteinase inhibitor, and is not beneficial 
for the fast-growing and invading glioblastoma cells; therefore, its basal expression level 
is low, and it is not elevated by IL-1. This allows the tumors to spread due to an increased 
net proteolytic activity, adhesiveness, and cell motility in response to IL-1. Thus far, 
inflammation has been associated with the centers of glioblastoma tumors, with IL-1 and 
IL-6 playing a major role in the progression and invasiveness of these tumors (166, 200). 
IL-1 is known to stimulate the migration and invasion of glioma cells through the 
induction of the plasminogen activator system (PAS) (109, 110), and activation of 
sphingosine kinase 1 (our unpublished data). Importantly, local levels of IL-1 correlate 
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with tumor invasiveness (6), and a poor prognosis in cancer patients and in experimental 
tumor models (60). Most GBMs produce IL-1 (133), while exogenous IL-1 induces the 
secretion of growth and invasiveness-promoting factors, such as bFGF, MMPs, 
angiogenic factors such as VEGF, and chemotactic factors such as IL-8 and MCP-1 in 
stromal cells, leukocytes, and in malignant cells (103). Despite the well-established role 
of IL-1 in tumorigenesis, neither OD tumors express significant levels of IL-1, nor do 
oligodendroglioma cells increase their proliferation in response to IL-1. In contrast, IL-6 
and OSM, which activate the JAK-STAT3 pathway, promote the proliferation of 
oligodendroglioma cells (Chapter 3). Although inflammation is associated with 
oligodendroglioma tumors, which abundantly express OSM, IL-6, MCP-1, MIP1α, and 
MIP1β, the question remains as to whether inflammation is the cause, or the symptom of 
tumor progression. IL-6 has been shown to induce autocrine proliferation of 
glioblastomas via the JAK-STAT3 pathway (166). Similarly, we show that IL-6 and 
OSM activate STAT3 and proliferation of oligodendroglioma cells, suggesting that a 
similar molecular mechanism exists in both GBMs and OD tumors. Interestingly enough, 
these two types of brain tumors do not share any molecular characteristics. Activated 
STAT3 exerts its effects in both tumor cells, and surrounding stromal cells (212). On one 
hand it drives proliferation and prevents apoptosis of tumor cells, and on the other it 
suppresses the anti-tumor immune response. This shared significance of STAT3 points to 
the fact that oligodendrocytes and astrocytes differentiate from the same glial precursor, 
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restricted to generate these glial cells, but not neurons. In fact, activation of the JAK-
STAT3 pathway is required for astrocyte differentiation (87), and it is triggered by 
neuron-derived CT-1 (12). It is also necessary for the maintenance and proliferation of 
neural progenitors, and the inhibition of neurogenesis. Since this pathway promotes the 
growth of progenitor and glial cells, it is also likely advantageous for the tumor cells, 
which sustain its activation. It is noteworthy that in glioblastomas, it is mostly the EGFR, 
or autocrine IL-6 signaling that leads to the activation of STAT3, and promotes cell 
growth (69, 167). In contrast, OSM activates STAT3 and proliferation in 
oligodendroglioma cells. Therefore, it is interesting that different stimuli cause STAT3 
activation and enhance proliferation of glioma cells and neural progenitors, and are also 
critical for normal gliogenesis. Critical roles of STAT3 in tumorigenesis and tumor 
maintenance have qualified it as a valid target for the development of novel anticancer 
therapies. Our findings suggest that STAT3 should be considered as a target for treatment 
of oligodendroglioma tumors. There are several strategies that may be employed to target 
the activated STAT3, including the use of Tyrosine kinase inhibitors or receptor 
antagonists, and the disruption of STAT3 dimerization by peptidomimetics or non-
peptide analogs. To date, several studies show that direct inhibition of persistently active 
STAT3 induces apoptosis of malignant cells, and induces tumor regression (96, 99, 166). 
The role of STAT3 in glial differentiation (87) is very prominent, whereas its 
contribution to gliomagenesis is under investigation. Currently, the origin of glioma 
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tumors is still debated. On one hand, the dedifferentiation theory is based on the 
similarities of astrocytomas to astrocytes and oligodendrogliomas to oligodendrocytes. 
Furthermore, these cells express compatible markers such as GFAP, BFABP in 
astrocytes/astrocytomas (71), and Olig genes in oligodendrocytes/oligodendrogliomas 
(132). On the other hand, there is an emerging evidence for the existence of CD133+ 
positive cancer stem cells, which may give rise to glioma tumors (14, 185, 186). These 
CD133+ cells are multipotent, which is reflected in the common heterogeneity of glioma 
tumors, and are characterized by high self-renewal capacity. The brain cancer stem cell 
theory is additionally based on the fact that glioma tumors often depend on the activation 
of developmental signaling, such as the Wnt, Notch, and Hedgehog pathways, which are 
often required for stem cell maintenance (169). Components of the Notch pathway 
control stem cell proliferation, and act as oncogenes in tumors, including astrocytomas 
and oligodendrogliomas (39). The Sonic Hedgehog (SHH) pathway is commonly 
activated in brain, prostate and skin tumors, and it is required to sustain their growth 
(175). Indeed, Gli transcription factors that are regulated by SHH are highly expressed in 
gliomas (42). Moreover, glioma tumors downregulate the expression of cell specific 
markers, such as GFAP, which inversely correlates with the glioma grade (202). 
Significantly, we demonstrated that NFI-X regulates GFAP expression in glioma cells 
and astrocytes (75), and it is indispensable for GFAP expression during astrocyte 
differentiation (Chapter 4). Moreover, NFI-X expression levels are lower in several 
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glioblastoma cell lines when compared to human primary astrocytes (data not shown). 
Furthermore, we show that NFI-X is required for the terminal differentiation of 
astrocytes, characterized by GFAP and SPARCL1 expression. Indeed, the SPARCL1 
expression levels are downregulated in glioma cells (data not shown). Intriguingly, 
SPARCL1 is known as the tumor suppressor, which has anti-proliferative and counter-
adhesive properties (39). These observations suggest that glioma cells are characterized 
by a gene expression pattern, which resembles dedifferentiated astrocytic cells, or 
alternatively that did not complete terminal differentiation. In this context, full 
comprehension of mechanisms of astrocyte differentiation, and the role of NFI in this 
process, is critical.  
The most fascinating questions revolve around the connection between the 
gliogenic JAK-STAT3 pathway, and NFI-X. It is unclear whether STAT3 regulates NFI-
X expression, or whether these two transcription factors form a complex by protein-
protein interactions. Importantly, the JAK-STAT3 pathway is also required for the 
survival, proliferation, and differentiation of oligodendrocyte precursors (52). Since MBP 
expression also depends on NFI (41), it is tempting to speculate that NFI may be 
important to a larger glial cell population, including oligodendrocytes. Thus, whereas 
NFI-X is crucial for astrocyte differentiation, other NFI isoforms may be relevant in 
oligodendrocyte differentiation. However, all of these exciting questions remain to be 
investigated and answered in future projects. This dissertation adds to the expanding data 
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on inflammation-induced mechanisms of gene regulation in brain cells, which are 
fascinating and promising in terms of finding new therapeutic targets for CNS diseases. 
Moreover, this thesis also contributes to resolving the mechanisms of cellular 
differentiation in the brain, which are likely critical for understanding the development 
and origin of brain tumors.  
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